



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number:

0 304 493
A1

(12)

EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

(21) Application number: **88902540.9**

(51) Int. Cl.³: **C 07 C 121/75**

C 07 C 120/00, C 07 D 207/38

(22) Date of filing: **10.03.88**

C 07 D 231/36, C 07 D 277/36

Data of the international application taken as a basis:

C 07 D 307/32, A 61 K 7/42

(86) International application number:
PCT/JP88/00254

A 61 K 31/275, A 61 K 31/34
A 61 K 31/425

(87) International publication number:
WO88/07035 (22.09.88 88/21)

Best Available Copy

(30) Priority: **11.03.87 JP 55965/87**
11.03.87 JP 55966/87
12.03.87 JP 57256/87

(71) Applicant: **KANEKA FUCHI KAGAKU KOGYO KABUSHIKI KAISHA**
2-4 Nakanoshima 3-chome
Kita-ku Osaka-shi Osaka-fu(JP)

(43) Date of publication of application:
01.03.89 Bulletin 89/9

(72) Inventor: **SHIRAISHI, Tadayoshi**
8-14, Nishihata 3-chome
Takasago-shi Hyogo 676(JP)






(84) Designated Contracting States:
BE CH DE FR GB IT LI NL SE

(72) Inventor: **KAMEYAMA, Keiji**
2-35, Hiraoka-cho Isshikinishi
Kakogawa-shi Hyogo 675-01(JP)

(72) Inventor: **DOMOTO, Takeshi**
Room 302 Mikihausu 310-7, Kakogawa-cho Hirano
Kakogawa-shi Hyogo 675(JP)

(54) HYDROXYSTYRENE DERIVATIVES.

(57) The invention is related to hydroxystyrene derivatives and salts thereof represented by general formula (I)



(wherein R³ and R⁴ are bound to each other to form -CONH-CS-S-, (II), (III) or (IV) (wherein R⁶ is (V) (wherein X¹ is H, halogen, methyl, ethyl, R⁷O- (wherein R⁷ is methyl or ethyl), nitro, aminosulfonyl, or amino and m¹ is 1 or 2), pyridyl, furyl or thienyl and n¹ is an integer of 0 to 3) when R¹ and R² each represents phenyl, benzyl or phenethyl or when R¹ represents R⁶O (wherein R⁶ is H, C₁-C₅ alkyl or benzyl) and R² represents benzyl or PhSCH₂; R³ represents cyano and R⁴ represents carbamoyl or they may be bound to each other to form -CO-Y-CH₂CH₂- (wherein Y is O or -NH) or (VI) when R¹ and R² each represents phenyl, benzyl or phenethyl or R¹ represents R⁶O- (wherein R⁶ is as defined above) and R² represents benzyl; or R³ and R⁴ are bound to each other to form (IV) (wherein n¹ and R⁶ are as defined above) when R¹ and R² each represents C₁-C₃ alkyl). They are useful as effective ingredients of anti-allergic agents, 5-lipoxygenase inhibitors, antibacterial agents, tyrosine kinase inhibitors, UV absorbers, and reverse transcriptase inhibitors, and are also useful as intermediates for many organic compounds.

- (72) Inventor: IMAI, Naohiro
951-9, Noguchi-cho Nagasuna
Kakogawa-shi Hyogo 675(JP)
- (72) Inventor: SHIMADA, Yoshio
321-2, Kakogawa-cho Kahara
Kakogawa-shi Hyogo 675(JP)
- (72) Inventor: ARIKI, Yutaka
925-9, Oshio-cho
Himeji-shi Hyogo 671-01(JP)
- (72) Inventor: HOSOE, Kazunori
8-5, Nishihata 3-chome
Takasago-shi Hyogo 676(JP)
- (72) Inventor: KAWATSU, MasaJI
63, Takasago-cho Okihamamachi 2-chome
Takasago-shi Hyogo 676(JP)
- (72) Inventor: KATSUMI, Ikuo
22-31, Chidorigaoka 3-chome Tarumi-ku
Kobe-shi Hyogo 655(JP)
- (72) Inventor: HIDAKA, Takayoshi
21-8, Hontamon 2-chome Tarumi-ku
Kobe-shi Hyogo 655(JP)
- (72) Inventor: WATANABE, Kiyoshi
15-41, Matsugaoka 5-chome
Akashi-shi Hyogo 673(JP)
- (74) Representative: Türk, Gille, Hrabal
Bruckner Strasse 20
D-4000 Düsseldorf 13(DE)

DESCRIPTION

HYDROXYSTYRENE DERIVATIVES

5

TECHNICAL FIELD

The present invention relates to a novel hydroxystyrene derivative or a salt thereof, which has antiallergic activity, 5-lipoxygenase inhibiting activity, antibacterial activity, tyrosine kinase inhibiting activity, ultraviolet (hereinafter referred to as "UV") absorbing activity and reverse transcriptase inhibiting activity and is useful as an intermediate for preparing various organic compounds, and relates to an antiallergic agent, a 5-lipoxygenase inhibiting agent, an 10 antibacterial agent, a tyrosine kinase inhibiting agent, an 15 UV absorber and a reverse transcriptase inhibiting agent containing the same as an active ingredient.

20

BACKGROUND ART


The compound of the present invention is a novel compound which has not yet been reported in a literature and is first synthesized by the present inventors.

25

DISCLOSURE OF THE INVENTION

It has now been found that a novel hydroxystyrene derivative of the present invention is a useful intermediate for preparing various organic compounds and has itself antiallergic activity, 5- 30 lipoxygenase inhibiting activity, antibacterial activity, tyrosine kinase inhibiting activity, UV absorbing activity and reverse transcriptase inhibiting activity.

In accordance with the present invention, there is provided a hydroxystyrene derivative represented by 35 the formula (I):



5 wherein when R^1 and R^2 are the same or different and each
is phenyl group, benzyl group or phenethyl group, or R^1
is a group having the formula: R^5O^- in which R^5 is
hydrogen atom, an alkyl group having 1 to 5 carbon atoms
or benzyl group and R^2 is benzyl group or a group of
10 $PhSCH_2$ in which Ph is phenyl group, hereinafter the same,
 R^3 and R^4 are taken together to represent a group having
the formula: $-CONH-CS-S-$, a group having the formula:

15 $-CONH-\overset{\text{C}_6\text{H}_5}{\text{C}_6\text{H}_4}-$, a group having the formula: $-CONH-\overset{\text{C}_6\text{H}_5}{\text{C}_6\text{H}_4}-SO_2^-$
or a group having the formula: $-CO-N=C-S-$ in which
 $NH(CH_2)_n^1R^6$
 R^6 is a group having the formula: $\overset{\text{C}_6\text{H}_5}{\text{C}_6\text{H}_4}(X^1)^{m^1}$ [in which

20 X^1 is hydrogen atom, a halogen atom, methyl group, ethyl
group, an alkoxy group having the formula: R^7O^- (in
which R^7 is methyl group or ethyl group), nitro group,
aminosulfonyl group or amino group, and m^1 is 1 or 2],
pyridyl group, furyl group or thienyl group, and n^1 is 0
25 or an integer of 1 to 3; when R^1 and R^2 are the same or
different and each is phenyl group, benzyl group or
phenethyl group, or R^1 is a group having the formula:
 R^5O^- in which R^5 is as defined above, and R^2 is benzyl
group, R^3 is cyano group and R^4 is carbamoyl group, or R^3
30 and R^4 are taken together to represent a group having the
formula: $-CO-Y-CH_2CH_2-$ in which Y is oxygen atom or $-NH-$,
or a group having the formula: $-CO-N-NH-CO-$; and
 Ph

35 when R^1 and R^2 are the same or different and each is an
alkyl group having 1 to 3 carbon atoms, R^3 and R^4 are
taken together to represent a group having the formula:
 $-CO-N=C-S-$ in which n^1 and R^6 are as defined above,
 $NH(CH_2)_n^1R^6$

or a salt thereof.

The compound having the formula (I) of the present invention can form a salt with a base or an acid. The salt of the present invention may be any which 5 can be formed from the compound of the present invention and the base or the acid.

Examples of the salt with the base are, for instance, (1) a salt with metal, especially an alkali metal salt, an alkaline earth metal salt and a salt with 10 aluminum; (2) an ammonium salt; and (3) an amine salt, especially a salt with methylamine, ethylamine, diethylamine, triethylamine, pyrrolidine, piperidine, morpholine, hexamethyleneimine, aniline or pyridine, and the like.


15 Examples of the salt with the acid are, for instance, (1) a salt with an inorganic acid, especially a salt with hydrochloric acid, sulfuric acid, phosphoric acid, nitric acid or carbonic acid; (2) a salt with an organic acid, especially a salt with a carboxylic acid such as formic acid, acetic acid, propionic acid, succinic acid, oxalic acid, tartaric acid, maleic acid, lactic acid, benzoic acid, anthranilic acid or salicylic acid; a salt with a sulfonic acid such as p-toluenesulfonic acid or methanesulfonic acid; a salt with 20 an amino acid such as glycine, methionine or lysine; and the like.

When the salts are employed for the antiallergic agent, the 5-lipoxygenase inhibiting agent, the antibacterial agent, the tyrosine kinase inhibiting 30 agent, the UV absorber or the reverse transcriptase inhibiting agent, the pharmaceutically acceptable salts should be employed.

As typical examples of the compounds of the invention, the compounds (1) to (45) are shown in Table 1 35 by showing the groups R¹, R², R³ and R⁴ in the formula (I), and further, exemplifying the group R⁶ and n¹ in case that R³ and R⁴ are taken together to represent a

group having the formula: $-CO-N=C-S-$
 $NH(CH_2)_n^1R^6$. Also, the
molecular formula, molecular weight, melting point, and
data of elementary analysis of each compound of (1) to
5 (45) are shown in Table 1. The results of 1H -NMR
spectrum analysis and IR spectrum analysis of the
compounds (1) to (45) are shown in Table 2.

Table 1

Compound No.	R ¹	R ²	R ³	R ⁴	R ⁶	n ¹	Molecular formula (Molecular weight)
1	Ph	Ph	-CONH-CS-S-	-	-	-	C ₂₂ H ₁₅ NO ₂ S ₂ (389.50)
2	PhCH ₂	PhCH ₂	-CONH-CS-S-	-	-	-	C ₂₄ H ₁₉ NO ₂ S ₂ (417.55)
3	Ph	Ph	-CONH-		-	-	C ₂₇ H ₁₉ NO ₂ (389.43)
4	PhCH ₂	PhCH ₂	-CONH-		-	-	C ₂₉ H ₂₃ NO ₂ (417.48)
5	PhCH ₂	PhCH ₂	-CONH-		-	-	C ₂₉ H ₂₃ NO ₄ S (481.57)

- continued -

- continued -

Compound No.	Melting point (°C)	Elementary analysis					
		C		H		N	
		Found (%)	Calcd. (%)	Found (%)	Calcd. (%)	Found (%)	Calcd. (%)
1	220 to 222	68.13	67.84	3.95	3.88	3.81	3.60
2	223 to 225	69.37	69.04	4.44	4.59	3.05	3.35
3	223 to 225	83.49	83.27	5.03	4.92	3.89	3.60
4	179 to 181	83.36	83.43	5.60	5.55	3.54	3.36
5	208 to 209	72.68	72.33	4.77	4.81	3.18	2.91

- continued -

0304493

- continued -

Compound No.	R ¹	R ²	R ³	R ⁴	R ⁶	n ¹	Molecular formula (Molecular weight)
6	C ₂ H ₅ O	PhSCH ₂	-CONH-CS-S-	-	-	-	C ₁₉ H ₁₇ NO ₃ S ₃ (403.54)
7	HO	PhSCH ₂	-CONH-CS-S-	-	-	-	C ₁₇ H ₁₃ NO ₃ S ₃ (375.49)
8	PhCH ₂ O	PhSCH ₂	-CONH-CS-S-	-	-	-	C ₂₄ H ₁₉ NO ₃ S ₃ (465.61)
9	n-C ₄ H ₉ O	PhSCH ₂	-CONH-CS-S-	-	-	-	C ₂₁ H ₂₁ NO ₃ S ₃ (431.60)
10	n-C ₄ H ₉ O	PhCH ₂	-CONH-CS-S-	-	-	-	C ₂₁ H ₂₁ NO ₃ S ₂ (399.53)

- continued -

- continued -




0394493

Compound No.	Melting Point (°C)	Elementary analysis					
		C		H		N	
		Found (%)	Calcd. (%)	Found (%)	Calcd. (%)	Found (%)	Calcd. (%)
6	190 to 191	56.37	56.55	4.44	4.25	3.58	3.47
7	189 to 192	54.62	54.38	3.61	3.49	3.55	3.73
8	161 to 163	62.08	61.91	3.99	4.11	2.65	3.01
9	189 to 190	58.08	58.44	5.02	4.90	3.63	3.25
10	210 to 212	63.37	63.13	5.18	5.30	3.75	3.51

- continued -

- continued -

- 9 -

Compound No.	R ¹	R ²	R ³	R ⁴	R ⁶	n ¹	Molecular formula (Molecular weight)
11	HO	PhSCH ₂	-CONH-		-	-	C ₂₂ H ₁₇ NO ₃ S (375.45)
12	PhCH ₂ O	PhSCH ₂	-CONH-		-	-	C ₂₉ H ₂₃ NO ₃ S (465.57)
13	CH ₃ O	PhCH ₂	-CONH-		-	-	C ₂₃ H ₁₉ NO ₃ (357.39)
14	n-C ₄ H ₉ O	PhCH ₂	-CONH-		-	-	C ₂₆ H ₂₅ NO ₃ (399.49)
15	Ph	Ph	CN, CONH ₂		-	-	C ₂₂ H ₁₆ N ₂ O ₂ (340.36)

- continued -

- continued -

Elementary analysis

Compound No.	Melting point (°C)	C		H		N	
		Found (%)	Calcd. (%)	Found (%)	Calcd. (%)	Found (%)	Calcd. (%)
11	190 to 191	70.63	70.39	4.68	4.57	3.39	3.73
12	155 to 158	74.56	74.82	5.13	4.98	3.37	3.01
13	228 to 231	77.30	77.30	5.59	5.36	4.05	3.92
14	185 to 186	78.42	78.17	6.12	6.31	3.82	3.51
15	179 to 181	77.81	77.63	4.71	4.74	8.51	8.23

- continued -

0304493

10 -

- continued -

Compound No.	R ¹	R ²	R ³	R ⁴	R ⁶	n ¹	Molecular formula (Molecular weight)
16	PhCH ₂	PhCH ₂	CN, CONH ₂		-	-	C ₂₄ H ₂₀ N ₂ O ₂ (368.42)
17	PhCH ₂	PhCH ₂		-COOCH ₂ CH ₂ -	-	-	C ₂₅ H ₂₂ O ₃ (370.45)
18	PhCH ₂	PhCH ₂		-CONHCH ₂ CH ₂ -	-	-	C ₂₅ H ₂₃ NO ₂ (369.46)
19	Ph	Ph		-CON-NHCO-	-	-	C ₂₈ H ₂₀ N ₂ O ₃ (432.48)
20	PhCH ₂	PhCH ₂		-CON-NHCO-	-	-	C ₃₀ H ₂₄ N ₂ O ₃ (460.51)

- continued -

C304493

- continued -

Elementary analysis

Compound No.	Melting point (°C)	C		H		N	
		Found (%)	Calcd. (%)	Found (%)	Calcd. (%)	Found (%)	Calcd. (%)
16	150 to 158	78.01	78.24	5.31	5.47	7.98	7.60
17	167 to 168	80.92	81.05	5.97	5.99	-	-
18	157 to 159	81.45	81.26	6.46	6.28	3.50	3.79
19	231 to 232	77.43	77.76	4.49	4.66	6.61	6.48
20	202 to 203	78.13	78.24	5.16	5.25	6.32	6.08

- continued -

- continued -

Compound No.	R ¹	R ²	R ³	R ⁴	R ⁶	n ¹	Molecular formula (Molecular weight)
21	C ₂ H ₅ O	PhCH ₂	CN, CONH ₂	-	-	-	C ₁₉ H ₁₈ N ₂ O ₃ (322.35)
22	CH ₃ O	PhCH ₂	CN, CONH ₂	-	-	-	C ₁₈ H ₁₆ N ₂ O ₃ (308.32)
23	HO	PhCH ₂	CN, CONH ₂	-	-	-	C ₁₇ H ₁₄ N ₂ O ₃ (294.30)
24	HO	PhCH ₂	-CON-NHCO-	-	-	-	C ₂₃ H ₁₈ N ₂ O ₄ (386.41)
25	Ph	Ph	-CO-N=C-S-	Ph	1		C ₂₉ H ₂₂ N ₂ O ₂ S (462.57)
			NH(CH ₂)n ¹ R ⁶				

- continued -

- continued -

Elementary analysis

Compound No.	Melting point (°C)	C		H		N	
		Found (%)	Calcd. (%)	Found (%)	Calcd. (%)	Found (%)	Calcd. (%)
21	173 to 174	70.56	70.80	5.47	5.63	8.80	8.69
22	208 to 209	70.02	70.12	5.45	5.23	9.21	9.09
23	266 to 268	69.62	69.38	4.96	4.80	9.31	9.52
24	252 to 255	71.25	71.49	4.57	4.70	7.59	7.25
25	257 to 259	75.18	75.31	4.63	4.80	5.78	6.06

- 14 -

0304493

- continued -

- continued -

- 15 -

Compound No.	R ¹	R ²	R ³	R ⁴	R ⁶	n ¹	Molecular formula (Molecular weight)
26	PhCH ₂	PhCH ₂	-CO-N=C-S-	NH(CH ₂)n ¹ R ⁶	Ph	1	C ₃₁ H ₂₆ N ₂ O ₂ S (490.63)
27	HO	PhSCH ₂	-CO-N=C-S-	NH(CH ₂)n ¹ R ⁶		1	C ₂₂ H ₁₈ N ₂ O ₄ S ₂ (438.52)
28	C ₂ H ₅ O	PhSCH ₂	-CO-N=C-S-	NH(CH ₂)n ¹ R ⁶	Ph	1	C ₂₆ H ₂₄ N ₂ O ₃ S ₂ (476.62)
29	n-C ₄ H ₉ O	PhSCH ₂	-CO-N=C-S-	NH(CH ₂)n ¹ R ⁶	Ph	1	C ₂₈ H ₂₈ N ₂ O ₃ S ₂ (504.67)
30	n-C ₄ H ₉ O	PhCH ₂	-CO-N=C-S-	NH(CH ₂)n ¹ R ⁶	Ph	1	C ₂₈ H ₂₈ N ₂ O ₃ S (472.61)

- continued -

- continued -

Elementary analysis

Compound No.	Melting point (°C)	C		H		N	
		Found (%)	Calcd. (%)	Found (%)	Calcd. (%)	Found (%)	Calcd. (%)
26	245 to 246	75.67	75.90	5.21	5.34	5.99	5.71
27	244 to 246	60.54	60.27	4.27	4.14	6.02	6.39
28	194 to 196	65.18	65.52	5.01	5.08	5.53	5.88
29	175 to 176	66.87	66.65	5.63	5.59	5.84	5.55
30	144 to 145	71.41	71.17	6.08	5.97	5.66	5.93

16 -

C3C4493

- continued -

- 17 -

- continued -

Compound No.	R ¹	R ²	R ³	R ⁴	R ⁶	n ¹	Molecular formula (Molecular weight)
31	PhCH ₂ O	PhSCH ₂	-CO-N=C-S-	NH(CH ₂)n ¹ R ⁶		1	C ₂₉ H ₂₄ N ₂ O ₃ S ₃ (544.71)
32	i-C ₃ H ₇	i-C ₃ H ₇	-CO-N=C-S-	NH(CH ₂)n ¹ R ⁶	Ph	0	C ₂₂ H ₂₄ N ₂ O ₂ S (380.50)
33	i-C ₃ H ₇	i-C ₃ H ₇	-CO-N=C-S-	NH(CH ₂)n ¹ R ⁶	Ph	1	C ₂₃ H ₂₆ N ₂ O ₂ S (394.53)
34	i-C ₃ H ₇	i-C ₃ H ₇	-CO-N=C-S-	NH(CH ₂)n ¹ R ⁶	Ph	2	C ₂₄ H ₂₈ N ₂ O ₂ S (408.55)
35	i-C ₃ H ₇	i-C ₃ H ₇	-CO-N=C-S-	NH(CH ₂)n ¹ R ⁶		1	C ₂₃ H ₂₅ N ₂ O ₂ SF (412.52)

- continued -

- continued -

Compound No.	Melting point (°C)	Elementary analysis					
		C		H		N	
		Found (%)	Calcd. (%)	Found (%)	Calcd. (%)	Found (%)	Calcd. (%)
31	152 to 153	64.23	63.95	4.57	4.44	4.85	5.14
32	213 to 216	69.31	69.45	6.30	6.36	7.63	7.36
33	180 to 183	70.18	70.03	6.58	6.64	7.27	7.10
34	144 to 146	70.43	70.56	7.02	6.91	7.08	6.86
35	172 to 175	66.76	66.98	6.24	6.11	6.99	6.79

- 18 -

0304493

- continued -

- continued -

Compound No.	R ¹	R ²	R ³	R ⁴	R ⁶	n ¹	Molecular formula (Molecular weight)
36	i-C ₃ H ₇	i-C ₃ H ₇	-CO-N=C-S-	NH(CH ₂)n ¹ R ⁶	-C ₆ H ₄ -C ₆ H ₄ -	1	C ₂₃ H ₂₅ N ₂ O ₂ SCl ₂ (428.97)
37	i-C ₃ H ₇	i-C ₃ H ₇	-CO-N=C-S-	NH(CH ₂)n ¹ R ⁶	-C ₆ H ₄ -C ₆ H ₄ -	1	C ₂₃ H ₂₄ N ₂ O ₂ SCl ₂ (463.41)
38	i-C ₃ H ₇	i-C ₃ H ₇	-CO-N=C-S-	NH(CH ₂)n ¹ R ⁶	-C ₆ H ₄ -OCH ₃	1	C ₂₄ H ₂₈ N ₂ O ₃ S (424.55)
39	i-C ₃ H ₇	i-C ₃ H ₇	-CO-N=C-S-	NH(CH ₂)n ¹ R ⁶	-C ₆ H ₄ -CH ₃	1	C ₂₄ H ₂₈ N ₂ O ₃ S (408.55)
40	i-C ₃ H ₇	i-C ₃ H ₇	-CO-N=C-S-	NH(CH ₂)n ¹ R ⁶	-C ₆ H ₄ -NO ₂	1	C ₂₃ H ₂₅ N ₃ O ₄ S (439.53)

- continued -

- continued -

0304493

- 20 -

Compound No.	Melting point (°C)	Elementary analysis					
		C		H		N	
		Found (%)	Calcd. (%)	Found (%)	Calcd. (%)	Found (%)	Calcd. (%)
36	184 to 186	64.56	64.40	5.98	5.87	6.77	6.53
37	140 (decomp.)	59.37	59.61	5.43	5.22	5.68	6.05
38	169 to 174	67.52	67.90	6.83	6.65	7.03	6.05
39	155 to 157	70.80	70.56	6.99	6.91	6.47	6.86
40	128 to 131	62.62	62.86	5.61	5.73	9.31	9.56

- continued -

- 21 -

Compound No.	R ¹	R ²	R ³	R ⁴	R ⁶	n ¹	Molecular formula (Molecular weight)
41	i-C ₃ H ₇	i-C ₃ H ₇	-CO-N=C-S-	NH(CH ₂)n ¹ R ⁶		1	C ₂₃ H ₂₇ N ₃ O ₄ S ₂ (478.60)
42	i-C ₃ H ₇	i-C ₃ H ₇	-CO-N=C-S-	NH(CH ₂)n ¹ R ⁶		1	C ₂₃ H ₂₇ N ₃ O ₂ S (409.55)
43	i-C ₃ H ₇	i-C ₃ H ₇	-CO-N=C-S-	NH(CH ₂)n ¹ R ⁶		1	C ₂₁ H ₂₄ N ₂ O ₃ S (384.48)
44	i-C ₃ H ₇	i-C ₃ H ₇	-CO-N=C-S-	NH(CH ₂)n ¹ R ⁶		1	C ₂₁ H ₂₄ N ₂ O ₂ S ₂ (400.55)
45	i-C ₃ H ₇	i-C ₃ H ₇	-CO-N=C-S-	NH(CH ₂)n ¹ R ⁶		1	C ₂₂ H ₂₅ N ₃ O ₂ S (395.52)

- continued -

- continued -

0304493

- 22 -

Compound No.	Melting point (°C)	Elementary analysis					
		C		H		N	
Found (%)	Calcd. (%)	Found (%)	Calcd. (%)	Found (%)	Calcd. (%)	Found (%)	Calcd. (%)
41	165 to 169	58.72	58.34	5.96	5.75	8.68	8.88
42	160 (decomp.)	67.63	67.46	6.53	6.65	10.57	10.26
43	179 to 180	65.38	65.61	6.37	6.29	7.41	7.29
44	180 to 183	63.31	62.99	6.18	6.04	6.71	7.00
45	110 to 113	66.53	66.82	6.49	6.37	10.98	10.63

Table 2

Compound No.	$^1\text{H-NMR}$ spectrum δ (ppm)	IR spectrum (cm $^{-1}$)
1	$\text{CDCl}_3/\text{DMSO-d}_6 = 1/1; 7.3-7.7(13\text{H},\text{m}),$ 9.01(1H,br), 13.4(1H,br)	KBr; 3540, 3150, 3050, 1700, 1590
2	$\text{CDCl}_3/\text{DMSO-d}_6 = 1/1; 4.03(4\text{H},\text{s}),$ 7.0-7.4(13H,m), 9.27(1H,br), 13.55(1H,br)	KBr; 3330, 3300, 1680, 1570
3	$\text{CDCl}_3/\text{DMSO-d}_6 = 1/1; 6.7-7.8(16\text{H},\text{m}),$ 8.33(1H,s), 8.6(1H,br), 10.4(1H,br)	KBr; 3550, 3180, 3050, 1695, 1620, 1590
4	$\text{CDCl}_3/\text{DMSO-d}_6 = 1/1; 4.05(4\text{H},\text{s}),$ 6.5-7.3(16H,m), 7.45(1H,s), 9.0(1H,br), 10.2(1H,br)	KBr; 3380, 3200, 1685, 1585
5	$\text{CDCl}_3/\text{DMSO-d}_6 = 1/1; 3.97(4\text{H},\text{s}),$ 7.1-7.8(16H,m), 7.75(1H,s), 9.5(1H,br)	KBr; 3450, 3200, 3060, 1680, 1600
6	$\text{CDCl}_3/\text{DMSO-d}_6 = 2/1; 1.40(3\text{H},\text{t}),$ 4.10(2H, q), 4.16(2H,s), 4.70(2H,d), 7.0-7.7(15H, m), 9.1-9.6(1H,br), 9.7-10.0(1H,br)	
7	$\text{CDCl}_3/\text{DMSO-d}_6 = 1/1; 4.15(2\text{H},\text{s}),$ 6.9(2H,s), 7.0-8.6(8H,m), 10.0(2H,br)	KBr; 3440, 3260, 1670, 1575
8	$\text{CDCl}_3/\text{DMSO-d}_6 = 1/1; 4.18(2\text{H},\text{s}),$ 5.18(2H,s), 6.8-7.6(13H,m), 9.7(1H,br)	KBr; 3520, 3120, 3050, 2850, 1675, 1570
9	$\text{CDCl}_3/\text{DMSO-d}_6 = 1/1; 0.98(3\text{H},\text{t}),$ 1.2-1.9(4H,m), 4.05(2H,t), 4.17(2H,s), 6.97(2H,s), 7.0-7.3(5H,m), 7.42(1H,s), 9.45(1H,br), 13.4(1H,br)	KBr; 3480, 3130, 3050, 2850, 1675, 1570
10	$\text{CDCl}_3/\text{DMSO-d}_6 = 1/1; 0.95(3\text{H},\text{t}),$ 1.3-2.0(4H,m), 3.93(2H,s), 4.02(2H,t), 6.8-7.4(7H,m), 7.45(1H,s), 9.28(1H,br)	KBr; 3480, 3130, 3020, 2950, 2850, 1685, 1570
11	$\text{CDCl}_3/\text{DMSO-d}_6 = 1/1; 4.19(2\text{H},\text{s}),$ 6.7-7.8(12H,m), 9.3(2H,br), 10.3(1H,br)	KBr; 3420, 3180, 1705, 1590

- continued -

- continued -

Compound No.	$^1\text{H-NMR}$ spectrum δ (ppm)	IR spectrum (cm $^{-1}$)
12	$\text{CDCl}_3/\text{DMSO-d}_6 = 1/1; 4.22(2\text{H},\text{s}), 5.25(2\text{H},\text{s}), 6.7-7.7(16\text{H},\text{m}), 8.87(1\text{H},\text{d}), 9.3(1\text{H},\text{br}), 10.3(1\text{H},\text{br})$	KBr; 3505, 3150, 3080, 3050, 3020, 1670, 1615, 1580
13	$\text{CDCl}_3/\text{DMSO-d}_6 = 1/1; 3.97(3\text{H},\text{s}), 4.00(2\text{H},\text{s}), 6.7-7.6(11\text{H},\text{m}), 8.77(1\text{H},\text{d}), 9.2(1\text{H},\text{br}), 10.4(1\text{H},\text{br})$	KBr; 3400, 3170, 3060, 1690, 1620, 1610, 1580
14	$\text{CDCl}_3/\text{DMSO-d}_6 = 1/1; 0.94(3\text{H},\text{t}), 1.3-1.9(4\text{H},\text{m}), 3.94(2\text{H},\text{s}), 4.00(2\text{H},\text{t}), 6.5-7.5(12\text{H},\text{m}), 8.9(1\text{H},\text{br}), 10.4(1\text{H},\text{br})$	KBr; 3160, 3130, 3060, 3020, 2950, 1685, 1610
15	$\text{CDCl}_3/\text{DMSO-d}_6 = 1/1; 7.3-7.8(12\text{H},\text{m}), 7.85(2\text{H},\text{s}), 8.15(1\text{H},\text{s}), 9.25(1\text{H},\text{s})$	KBr; 3500, 3475, 3300, 3200, 2205, 1710, 1580
16	$\text{CDCl}_3/\text{DMSO-d}_6 = 1/1; 4.00(4\text{H},\text{s}), 7.1-7.3(10\text{H},\text{m}), 7.4(2\text{H},\text{br}), 7.57(2\text{H},\text{s}), 7.90(1\text{H},\text{s}), 9.5(1\text{H},\text{br})$	KBr; 3400, 3320, 2205, 1660, 1565
17	$\text{CDCl}_3/\text{DMSO-d}_6 = 1/1; 2.93(2\text{H},\text{t-d}), 4.00(4\text{H},\text{s}), 4.30(2\text{H},\text{t}), 7.0-7.3(13\text{H},\text{m}), 9.0(1\text{H},\text{br})$	KBr; 3360, 1720, 1645, 1590
18	$\text{CDCl}_3/\text{DMSO-d}_6 = 1/1; 2.77(2\text{H},\text{m}), 3.30(2\text{H},\text{m}), 3.97(4\text{H},\text{s}), 6.8-7.5(13\text{H},\text{m}), 7.8(1\text{H},\text{br}), 8.8(1\text{H},\text{br})$	KBr; 3400, 3200, 2900, 1685, 1640, 1600, 1580
19	$\text{CDCl}_3/\text{DMSO-d}_6 = 1/1; 7.0-8.0(16\text{H},\text{m}), 8.48(1\text{H},\text{s}), 8.53(1\text{H},\text{s}), 9.3(1\text{H},\text{br})$	KBr; 3530, 3220, 3080, 1720, 1660, 1620, 1570
20	$\text{CDCl}_3/\text{DMSO-d}_6 = 1/1; 4.00(4\text{H},\text{s}), 7.0-7.9(16\text{H},\text{m}), 8.3(1\text{H},\text{s}), 8.35(1\text{H},\text{s}), 9.8(1\text{H},\text{br})$	KBr; 3150, 3060, 3020, 1700, 1655, 1620, 1570
21	$\text{CDCl}_3/\text{DMSO-d}_6 = 1/1; 1.43(3\text{H},\text{t}), 3.97(2\text{H},\text{s}), 4.12(2\text{H},\text{q}), 7.1-7.3(6\text{H},\text{m}), 7.43(2\text{H},\text{br}), 7.60(1\text{H},\text{d}), 8.00(1\text{H},\text{s}), 9.30(1\text{H},\text{br})$	KBr; 3520, 3380, 3170, 2205, 1685, 1575

- continued -

- continued -

Compound No.	$^1\text{H-NMR}$ spectrum δ (ppm)	IR spectrum (cm $^{-1}$)
22	$\text{CDCl}_3/\text{DMSO-d}_6 = 1/1; 3.87(3\text{H},\text{s}), 3.93(2\text{H},\text{s}), 7.1-7.3(6\text{H},\text{m}), 7.40(2\text{H},\text{br}), 7.60(1\text{H},\text{d}), 7.98(1\text{H},\text{s}), 9.5(1\text{H},\text{br})$	KBr; 3500, 3370, 3170, 2200, 1665, 1570
23	$\text{CDCl}_3/\text{DMSO-d}_6 = 1/1; 3.92(2\text{H},\text{s}), 7.06(1\text{H},\text{d}), 7.1-7.3(5\text{H},\text{m}), 7.4(2\text{H},\text{br}), 7.53(1\text{H},\text{d}), 7.87(1\text{H},\text{s}), 9.4(2\text{H},\text{br})$	KBr; 3440, 3310, 3250, 2210, 1660, 1590, 1570
24	$\text{CDCl}_3/\text{DMSO-d}_6 = 1/1; 3.90(2\text{H},\text{s}), 7.1-7.8(12\text{H},\text{m}), 8.38(1\text{H},\text{dd}), 9.9(2\text{H},\text{br})$	KBr; 3480, 3170, 1710, 1650, 1600, 1570
25	$\text{CDCl}_3/\text{DMSO-d}_6 = 1/1; 4.75(2\text{H},\text{d}), 7.3-7.7(18\text{H},\text{m}), 8.8(1\text{H},\text{br}), 9.84(1\text{H},\text{t})$	KBr; 3570, 3200, 2850, 1690, 1635, 1610, 1570
26	$\text{CDCl}_3/\text{DMSO-d}_6 = 1/1; 4.00(4\text{H},\text{s}), 4.82(2\text{H},\text{d}), 7.1-7.3(18\text{H},\text{m}), 9.0(1\text{H},\text{br}), 9.78(1\text{H},\text{t})$	KBr; 3300, 3200, 3010, 2880, 1660, 1610, 1590, 1570
27	$\text{CDCl}_3/\text{DMSO-d}_6 = 1/1; 4.13(2\text{H},\text{s}), 4.72(2\text{H},\text{s}), 6.37(2\text{H},\text{d}), 6.90(2\text{H},\text{s}), 7.2-7.5(6\text{H},\text{m}), 7.57(1\text{H},\text{d}), 9.8(3\text{H},\text{br})$	KBr; 3550, 3180, 2800, 1660, 1620, 1580
28	$\text{CDCl}_3/\text{DMSO-d}_6 = 2/1; 1.40(3\text{H},\text{t}), 4.10(2\text{H},\text{q}), 4.16(2\text{H},\text{s}), 4.70(2\text{H},\text{d}), 7.03-7.73(15\text{H},\text{m}), 9.10-9.60(1\text{H},\text{br}), 9.7-10.0(1\text{H},\text{br})$	
29	$\text{CDCl}_3/\text{DMSO-d}_6 = 1/1; 0.97(3\text{H},\text{t}), 1.3-2.0(4\text{H},\text{m}), 4.03(2\text{H},\text{t}), 4.13(2\text{H},\text{s}), 4.72(2\text{H},\text{s}), 6.9-7.5(13\text{H},\text{m})$	KBr; 3520, 3200, 3050, 2950, 2880, 1680, 1615, 1595
30	$\text{CDCl}_3/\text{DMSO-d}_6 = 1/1; 1.02(3\text{H},\text{t}), 1.3-1.9(4\text{H},\text{m}), 4.03(2\text{H},\text{s}), 4.08(2\text{H},\text{t}), 4.59(2\text{H},\text{s}), 6.88(2\text{H},\text{s}), 7.1-7.7(11\text{H},\text{m}), 8.0(1\text{H},\text{br})$	KBr; 3520, 3200, 3020, 2900, 2870, 1670, 1590
31	$\text{CDCl}_3/\text{DMSO-d}_6 = 1/1; 4.17(2\text{H},\text{s}), 4.87(2\text{H},\text{s}), 5.17(2\text{H},\text{s}), 6.9-7.6(16\text{H},\text{m}), 9.8(2\text{H},\text{br})$	KBr; 3500, 3200, 3060, 2770, 1680, 1630, 1610, 1590

- continued -

- continued -

Compound No.	$^1\text{H-NMR}$ spectrum δ (ppm)	IR spectrum (cm $^{-1}$)
32	CDC $\ddot{\text{O}}$ ₃ ; 1.30(12H,d), 3.12(2H,m), 7.10 (2H,d), 7.41(2H,s), 7.52(1H,br), 7.90 (1H,s), 10.21(1H,br)	
33	CDC $\ddot{\text{O}}$ ₃ /DMSO-d ₆ = 10/1; 1.20(12H,d), 3.30 (2H,m), 4.70(2H,s), 7.13(2H,s), 7.30 (5H,m), 7.56(1H,s), 9.30-9.80(1H,br)	
34	CDC $\ddot{\text{O}}$ ₃ /DMSO-d ₆ = 10/1; 1.23(12H,d), 2.96(2H,t), 3.40(2H,m), 3.80(2H,q), 7.20-7.40(7H,m), 7.53(1H,s), 8.40- 8.70(1H,br), 9.46(1H,t)	
35	CDC $\ddot{\text{O}}$ ₃ ; 1.23(12H,d), 3.36(2H,m), 4.76 (2H,d), 6.86-7.50(6H,m), 7.67(1H,s), 7.90-8.40(1H,br), 9.23-9.66(1H,br)	
36	CDC $\ddot{\text{O}}$ ₃ /DMSO-d ₆ = 10/1; 1.26(12H,d), 3.36(2H,m), 4.70(2H,s), 7.20(2H,s), 7.33(4H,s), 7.07 (1H,s), 8.00-8.40(1H,br), 9.10-9.70(1H,br)	
37	CDC $\ddot{\text{O}}$ ₃ /DMSO-d ₆ = 10/1; 1.23(12H,d), 3.33 (2H,m), 4.70(2H,d), 7.20-7.47(5H,m), 7.67 (1H,s), 7.80-8.20(1H,br), 9.20-9.60(1H,br)	
38	CDC $\ddot{\text{O}}$ ₃ /DMSO-d ₆ = 10/1; 1.16(12H,d), 3.33 (2H,m), 3.73(3H,s), 4.70(1H,s), 6.80(2H, d), 7.16(2H,s), 7.30(2H,d), 7.60(1H,s), 7.85-8.20(1H,br), 9.00-9.60(1H,br)	
39	CDC $\ddot{\text{O}}$ ₃ /DMSO-d ₆ = 10/1; 1.23(12H,d), 2.33(3H,s), 3.36(2H,m), 4.70(2H,d), 7.06-7.26(6H,m), 7.66(1H,s), 8.0-8.3(1H,br), 9.30(1H,t)	
40	CDC $\ddot{\text{O}}$ ₃ /DMSO-d ₆ = 10/1; 1.23(12H,d), 3.36 (2H,m), 4.87(2H,d), 7.16(2H,s), 7.50 (1H,s), 7.60(2H,d), 8.20(2H,d), 8.2-8.6 (1H,br), 9.67(1H,br)	

- continued -

- continued -

Compound No.	$^1\text{H-NMR spectrum}$ δ (ppm)	IR spectrum (cm $^{-1}$)
41	$\text{CDCl}_3/\text{DMSO-d}_6 = 10/1; 1.23(12\text{H},\text{d}),$ 3.16(2H,s), 3.33(2H,m), 4.80(2H,s), 6.96-7.90(7H,m), 8.0-8.4(1H,br), 9.63-9.76(1H,m)	
42	$\text{CDCl}_3/\text{DMSO-d}_6 = 10/1; 1.26(12\text{H},\text{d}), 3.30$ (2H,s), 3.36(2H,m), 4.66(2H,d), 6.63 (2H,d), 7.06(2H,d), 7.20(2H,s), 7.56 (1H,s), 8.4-8.8(1H,br), 9.5-9.7(1H,br)	
43	$\text{CDCl}_3/\text{DMSO-d}_6 = 10/1; 1.27(12\text{H},\text{d}), 3.36$ (2H,m), 4.80(2H,d), 6.36(2H,s), 7.26 (2H,s), 7.43(1H,s), 7.73(1H,s), 7.8-8.3 (1H,br), 9.1-9.5(1H,br)	
44	$\text{CDCl}_3/\text{DMSO-d}_6 = 10/1; 1.26(12\text{H},\text{d}), 3.36$ (2H,m), 4.96(2H,d), 6.9-7.3(5H,m), 7.73 (1H,s), 7.8-8.4(1H,br), 9.40(1H,t)	
45	$\text{CDCl}_3; 1.23(12\text{H},\text{d}), 3.23(2\text{H},\text{m}), 4.86$ (2H,d), 7.06-7.46(5H,m), 7.66(1H,d), 7.76(1H,s), 8.50(1H,d), 8.7-9.1(1H,br)	

The compound having the formula (I) of the present invention can be prepared by any processes as far as the compound can be obtained, and there are exemplified the following processes (a), (b) and (c) as 5 the preparation processes.

(a) The compound having the formula (I) can be prepared by a condensation reaction of a benzaldehyde having the formula (II):

10



wherein R⁸ and R⁹ are the same or different and each is 15 an alkyl group having 1 to 3 carbon atoms, phenyl group, benzyl group or phenethyl group, or R⁸ is a group having the formula: R¹¹O- in which R¹¹ is hydrogen atom, an alkyl group having 1 to 5 carbon atoms or benzyl group, and R⁹ is benzyl group or a group: PhSCH₂, and R¹⁰ is 20 hydrogen atom, an alkyl group having 1 to 3 carbon atoms, an alkyl group substituted with ethers, e.g. methoxymethyl group or methoxyethoxymethyl group, benzyl group, an acyl group having the formula: COR¹² in which R¹² is hydrogen atom or an alkyl group having 1 to 3 25 carbon atoms, or a trialkylsilyl group such as trimethylsilyl group or tert-butyldimethylsilyl group; and a compound having the formula (III):

30




wherein R¹³ is cyano group and R¹⁴ is carbamoyl group, or R¹³ and R¹⁴ are taken together to represent a group: 35 -CO-Y-CH₂CH₂- in which Y is oxygen atom or a group: -N(COR¹⁵)- in which R¹⁵ is hydrogen atom or an alkyl group having 1 to 3 carbon atoms, a group:


$-\text{CO}-\underset{\text{Ph}}{\text{N}}-\text{NHCO}-$, a group: $-\text{CONH}-\text{CS}-\text{S}-$, a group: $-\text{CONH}$ 

or a group: $-\text{CONH}$  SO_2^- ;

5 or a compound having the formula (IV):



10

wherein R^{16} is a group having the formula: 

[in which X^2 is hydrogen atom, a halogen atom, methyl group, ethyl group, an alkoxy group having the formula:

15

$R^{17}\text{O}^-$ (in which R^{17} is methyl group or ethyl group), nitro group, aminosulfonyl group or amino group, and m^1 is 1 or 2], pyridyl group, furyl group or thienyl group,

and n^2 is 0 or an integer of 1 to 3;

in the absence or presence of an acid or a base as a

20

catalyst.

Examples of the acid used as the catalyst in the above-mentioned reaction are, for instance, a proton acid such as sulfuric acid, benzenesulfonic acid or p-toluenesulfonic acid, a Lewis acid such as boron

25

trifluoride, and the like.

Examples of the base used as the catalyst are, for instance, ammonium or its salt, an organic base such as piperidine, pyrrolidine, monoethanolamine, pyridine, morpholine or 1,8-azabicyclo [5.4.0] undeca-7-ene or a

30

salt thereof, an alkali metal salt of organic acid such as sodium acetate or potassium acetate, an alkali metal hydroxide such as sodium hydroxide or potassium hydroxide, an alkali metal amide such as lithium diisopropylamide, an alkali metal alcoholate such as

35


sodium methylate or potassium butylate, an alkali metal hydride such as sodium hydride or potassium hydride, and the like.

When R^{10} in the starting material is remained

in the obtained product as an alkyl, an alkyl group substituted with ethers, benzyl, an acyl or trialkylsilyl group due to noncatalytic reaction or the kind of catalyst employed, the desired compound can be obtained 5 by eliminating R^{10} . For eliminating R^{10} , when R^{10} is an alkyl group or an alkyl group substituted with ethers, cleavage reaction which is carried out by using a Lewis acid such as aluminum chloride or boron tribromide, or a proton acid such as hydrogen bromide or trichloroacetic 10 acid, other ether bond cleavage reaction, or the like can be adopted. When R^{10} is benzyl group, catalytic reduction reaction can be employed which is carried out by using a noble metal catalyst such as palladium carbon, as well as the above-mentioned ether bond cleavage 15 reaction. When R^{10} is an acyl group, R^{10} can be eliminated by hydrolysis reaction which is carried out by using a base such as an alkali metal hydroxide such as sodium hydroxide or an alkaline earth metal hydroxide such as barium hydroxide. When R^{10} is trialkylsilyl 20 group, R^{10} can be eliminated with water, methanol, an acid, fluorine ion, or the like.


When the reaction is carried out by employing an N-acyllactam and an acyl group is remained in the obtained product, the acyl group can be eliminated by 25 hydrolysis reaction using a base such as alkali metal hydroxide such as sodium hydroxide to give the desired compound.

(b) The compound having the formula (I) can be prepared, according to O. Ister et al. [Helvetica Chimica 30 Acta (Helv. Chim. Acta), 40, 1242(1957)], G. A. Howie et al. [Journal of Medicinal Chemistry (J. Med. Chem.), 17, 840(1974)], H. Wamhoff et al. [Synthesis, 331(1976)], and the like, by reacting a benzaldehyde having the formula (V):



wherein R¹⁸ and R¹⁹ are the same or different and each is an alkyl group having 1 to 3 carbon atoms, phenyl group, benzyl group or phenethyl group, or R¹⁸ is a group: R²⁰O- in which R²⁰ is hydrogen atom, an alkyl group having 1 to 5 carbon atoms or benzyl group, and R¹⁹ is benzyl group or the group: PhSCH₂;

5 with an ylide having the formula (VI):



wherein Ar is an aryl group, R²¹ is a cyano group, and R²² is carbamoyl group, or R²¹ and R²² are taken together to represent a group having the formula:


15 -CO-Z-CH₂CH₂- in which Z is oxygen atom or -NH-, a group having the formula: -CON-NH-CO-, a group having the

$$\begin{array}{c} | \\ Ph \end{array}$$

formula: -CONH-CS-S-, a group having the formula:

20 -CONH- or a group having the formula: -CONH-SO₂-;

or an ylide having the formula (VII):




wherein R²³ is a group having the formula:  (X³)m³
[in which X³ is hydrogen atom, a halogen atom, methyl group, ethyl group, an alkoxy group having the formula:
30 R²⁴O- (in which R²⁴ is methyl group or ethyl group), nitro group, aminosulfonyl group or amino group, and m³ is 1 or 2], pyridyl group, furyl group or thiienyl group, and n³ is 0 or an integer of 1 to 3.

The above-mentioned reaction (b) is carried out
35 according to the so-called Wittig reaction. For the ylide in the reaction (b), a ylide derived from a trialkyl phosphine such as tributyl phosphine or a triaryl arsine such as triphenyl arsine can also be used


as well as the above-mentioned ylide (VI) or (VII).

(c) The compound, which is one of the embodiments of the present invention, having the formula (VIII):

5




10 wherein R²⁵ and R²⁶ are the same or different and each is an alkyl group having 1 to 3 carbon atoms, phenyl group, benzyl group or phenethyl group, or R²⁵ is a group having the formula: R²⁸O- in which R²⁸ is hydrogen atom, an alkyl group having 1 to 5 carbon atoms or benzyl group,
15 R²⁶ is benzyl group or the group: PhSCH₂, R²⁷ is a group having the formula:



20 atom, methyl group, ethyl group, an alkoxy group having the formula: R²⁹O- (in which R²⁹ is methyl group or ethyl group), nitro group, aminosulfonyl group or amino group, and m⁴ is 1 or 2], pyridyl group, furyl group or thienyl group, and n⁴ is 0 or an integer of 1 to 3, can be
25 prepared, according to M. T. Omar et al. [Acta Chimica Academiae Scientiarum Hungaricae (Acta Chim. Budapest)], 83, 359(1974); Indian Journal of Chemistry (Ind. J. Chem.) 20B, 849(1981)], by reacting a compound having the formula (IX):

30




35

wherein R³⁰ and R³¹ are the same or different and each is an alkyl group having 1 to 3 carbon atoms, phenyl group, benzyl group or phenethyl group, or R³⁰ is a group having

the formula: $R^{32}O^-$ in which R^{32} is hydrogen atom, an alkyl group having 1 to 5 carbon atoms or benzyl group, and R^{31} is benzyl group or a group: $PhSCH_2$; or a compound having the formula (X):


5



10 wherein R^{33} and R^{34} are the same or different and each is an alkyl group having 1 to 3 carbon atoms, phenyl group, benzyl group or phenethyl group, or R^{33} is a group having the formula: $R^{36}O^-$ in which R^{36} is hydrogen atom, an alkyl group having 1 to 5 carbon atoms or benzyl group,
15 R^{34} is benzyl group or a group: $PhSCH_2$, and R^{35} is an alkyl group having 1 to 3 carbon atoms; with an amine having the formula (XI):



20

wherein R^{37} is a group having the formula:  [in which X^5 is hydrogen atom, a halogen atom, methyl group, ethyl group, an alkoxy group having the formula: $R^{38}O^-$ (in which R^{38} is methyl group or ethyl group), nitro group, aminosulfonyl group or amino group, and m^5 is 1 or 2], pyridyl group, furyl group or thiienyl group, and n^5 is 0 or an integer of 1 to 3.

The novel hydroxystyrene derivative (I) of the present invention or a salt thereof is useful as an intermediate for preparing various organic compounds, and also useful as an antiallergic agent, 5-lipoxygenase inhibiting agent, an antibacterial agent, a tyrosine kinase inhibiting agent, an UV absorber or a reverse transcriptase inhibiting agent.

35

That is, the hydroxystyrene derivative can be expected to be used as an antiallergic agent and the like, by its antiallergic activity. By its 5-lipoxygenase inhibiting activity, it can be expected to

be used as an antiasthmatic agent, an antiinflammatory agent, agents for the treatments of psoriasis, nephritis and myocardial infarction, an agent for preventing myocardial infarction and the like. By its antibacterial activity, it can be expected to be used as an antibacterial agent. By its tyrosine kinase inhibiting activity, it can be used as an antiasthmatic agent, an antiinflammatory agent, an anti-cancer agent, a carcinogenesis preventing agent, a metastasis-preventing agent, an agent used for the treatment of mental disease and the like. By its UV absorbing activity, it can be expected to be used for the prevention of erythema solare, used for preventing the deterioration of materials of organic high molecular weight compounds due to ultraviolet rays, and the like. Also, by its reverse transcriptase inhibiting activity, it can be expected to be used as an agent for preventing virus infections.

The above-mentioned activities of the compound of the present invention are specifically described by the following tests. In Tables 3 to 9, each compound No. corresponds to the compound No. in Tables 1 and 2.

The antiallergic activity of the compound of the invention is proved by the tests of inhibitory activity against passive cutaneous anaphylaxis (hereinafter referred to as "PCA") reaction, protecting effect against antigen-induced anaphylactic shock death and protecting effect against antigen-induced airway constriction.

(1) Inhibitory activity against homologous PCA reaction
30 in rats

Antiserum was prepared according to I. Mota [Immunology, 7, 681(1964)] and the PCA reaction was conducted according to Maruyama et al. [Folia Pharmacologica Japonica, 74, 179(1978)].

35 PREPARATION OF ANTISERUM

An ovalbumin solution dissolved in physiological saline (2 mg/ml) was injected intramuscularly into both thighs of male Wistar rats

weighing 200 to 260 g in a volume of 0.5 ml/100 g body weight, and pertussis vaccine (*Bordetella pertussis*, 2 x 10¹⁰/ml, Chiba Serum Institute) was intraperitoneally administered at 1 ml/rat. Twelve days after 5 sensitization, blood was taken from posterior aorta under ether anesthesia and serum was separated and stored at -80°C.

PCA REACTION

In each group, 4 male Wistar rats weighing 180 10 to 210 g were used. Back of the rats was shaved and each 0.05 ml of antiserum diluted 32 times with physiological saline was injected intradermally at four sites on the back. After 48 hours, 1 ml of a mixture of ovalbumin (2 mg/ml) as an antigen and Evans blue (10 mg/ml) in the 15 volume ratio of 1 : 1, which was dissolved in physiological saline was injected intravenously into the tail. Thirty minutes later, the rats were bled to death under ether anesthesia and the back skin of the rats was removed. The blue-dyed area formed by pigment exudation 20 was measured and an inhibition rate (%) was calculated as compared with control according to the following equation.

$$25 \quad \text{Inhibition rate (\%)} = \frac{A - B}{A} \times 100$$

A: Blue-dyed area in the control group

B: Blue-dyed area in the test compound group

30 A test compound suspended in a 2.5 % aqueous solution of gum arabic containing 0.2 % Tween 80 was administered orally in a volume of 0.5 ml/100 g body weight 1 hour before the injection of antigen. To the control group, only the vehicle was administered. 35 Tranilast which was a positive control compound was administered orally 30 minutes before the injection of antigen. The result shown in Table 3 proves that the compound of the present invention shows an excellent PCA

reaction inhibitory activity.

Table 3

	Compound No.	Dose (mg/kg)	Inhibition rate (%)
5	23	100	29
	32	100	21
	33	100	50
10	34	100	48
	35	100	43
	37	100	21
	39	100	65
	41	100	25
15	tranilast	300	40

(2) Protecting effect against antigen-induced
anaphylactic shock death in actively sensitized
guinea pigs

Anaphylactic shock death caused by inhalation
of antigen was observed according to John P. Devlin
[Pulmonary and Antiallergic Drugs, John Wiley & Sons,
155(1985)] employing actively sensitized guinea pigs.

Each 100 mg/kg of body weight ovalbumin
dissolved in physiological saline was injected into
gluteus and into peritoneal cavity of male guinea pigs
weighing 250 to 350 g. Three days later, the animals
were further injected intraperitoneally with ovalbumin
30 (100 mg/kg body weight) to conduct booster. Those
animals were employed for testing 3 to 4 weeks after the
sensitization.

In each group, 4 or more actively sensitized
guinea pigs were pretreated by subcutaneously injecting
35 pyrilamine (1 mg/kg body weight) 30 minutes before
antigen inhalation to suppress histamine-dependent
response and propranolol (1 mg/kg body weight) to enhance
the response induced by other than histamine 10 minutes

before the antigen inhalation.

The animal was placed in a desiccator with a capacity of about 5 l and 0.5 % aqueous solution of ovalbumin in the state of aerosol was inhaled with ultrasonic type nebulizer for five minutes. Anaphylactic shock death was observed and the animals survived for 90 minutes or more after antigen inhalation were estimated to be protected. All the animals of the control group died due to anaphylactic shock. The results are shown in Table 4. The compounds of the present invention and therapeutic antiasthmatic agent (tranilast, theophylline) were administered orally 30 minutes before the antigen inhalation. The result shown in Table 4 proves that the compounds of the present invention shows an excellent protecting effect against antigen-induced anaphylactic shock death.

Table 4

20	Compound No.	Dose (mg/kg)	Protecting effect*
	35	10	2/4
	36	100	1/4
	37	100	1/4
25	38	100	1/4
	39	100	1/4
	41	10	1/4
	tranilast	100	0/4
	theophylline	30	2/4
30	control	-	0/20

(note) * Number of survivors/Number of animals used

(3) Inhibitory activity against antigen-induced airway constriction in actively sensitized guinea pigs
 According to Orange and Moore [Journal of Immunology (J. Immunol.), 116, 392(1976)], an emulsion of a solution of ovalbumin dissolved in physiological saline

(2 mg/ml) and Freund's complete adjuvant (Difco Laboratories), mixed in the equal volume was injected into peritoneal cavity of guinea pigs in the volume of 1 ml/guinea pig to sensitize them. Three or four weeks later, airway contraction caused by antigen-antibody reaction was measured in accordance with Konzett Rossler [Archiv für Experimental Pathologie und Pharmakologie (Arch. Exp. Path. Pharmak.), 195, 71(1940)]. That is, the sensitized guinea pigs (5 guinea pigs/group) were provided with artificial respiration by inserting a tracheal cannula under urethane anesthesia (1.5 g/kg body weight, intraperitoneal administration), and then, gallamine at 1 mg/kg body weight was injected intravenously to stop spontaneous respiration of the guinea pigs. Inhalation of 0.5 % aqueous solution of ovalbumin was conducted using a nebulizer for 1 minute to increase antigen-induced airway constriction, at the same time, airway pressure was recorded through a transducer. Test compound was administered into jugular vein (i.v.) of the guinea pig 3 minutes before the antigen inhalation or administered orally (p.o.) 2 hours before the antigen inhalation. As a positive control compound, theophylline which was a drug for anti-asthma was used. The effect of the compound was estimated by calculating the maximum value of airway constriction (%) in comparison with the control group, according to the following equation. The result is shown in Table 5.

$$30 \quad \text{Inhibition rate (\%)} = \frac{A - B}{A} \times 100$$

A: Maximum value of airway constriction in the control group

35 B: Maximum value of airway constriction in the test compound group

The result shown in Table 5 proves that the

compounds of the present invention shows excellent inhibitory activity against antigen-induced airway constriction.

5

Table 5

	Compound No.	Route of administration	Dose (mg/kg)	Inhibition rate (%)
10	7	i.v.	1	25
	8	i.v.	1	43
	9	i.v.	1	20
	11	i.v.	1	52
	11	p.o.	30	26
15	12	i.v.	1	32
	26	i.v.	1	68
	32	i.v.	2	23
	33	i.v.	2	26
	37	i.v.	1	21
20	39	i.v.	1	59
	42	i.v.	5	33
	43	i.v.	5	21
	45	i.v.	1	42
	theophylline	i.v.	1	31
25				

5-Lipoxygenase inhibiting activity of the compound of the present invention was measured referring to the method for measuring 5-lipoxygenase activity by K. Ochi et al. [Journal of Biological Chemistry (J. Biol. Chem.), 258, 5754(1983)].

Sterilized 2 % solution of casein (pH 7) was injected intraperitoneally into Hartley guinea pigs in a volume of 5 ml/100 g body weight. Fifteen hours later, the guinea pigs were killed and peritoneal exudate cells thereof were collected. After the exudate cells were washed with 17 mM Tris-HCl buffer (pH 7.4) containing 0.74 % ammonium to remove contaminating erythrocytes in

the exudate cells suspension, the cells were washed with buffer A (130 mM NaCl, 1 mM EDTA, 25 mM sodium phosphate, pH 7.4). The washed cells were suspended in buffer B (50 mM sodium phosphate, 1 mM EDTA, 0.1 % gelatin, pH 7.4) at 10⁸ cells/ml, sonicated and centrifuged at 10,000 x g for 20 minutes under the cold atmosphere. The obtained supernatant was further centrifuged at 105,000 x g for 60 minutes under the cold atmosphere. The cytosol fraction was used as an enzyme solution.

10 The enzyme solution was preincubated with the test compound in the presence of 1mM CaCl₂, 1 mM reduced glutathione (GSH) and 2mM ATP at 30°C for 5 minutes in 0.2 ml of a reaction mixture and the mixture was further incubated at 30°C for 5 minutes by adding 20 µM [1-¹⁴C] arachidonic acid (0.1 µCi) thereto. The test compounds were dissolved in ethanol to give the reaction mixture containing 2 % ethanol as a final concentration. Only ethanol was added to the reaction mixture as a control group.

20 To the reaction mixture were added 2.5 ml of a mixture of chloroform and methanol (2/1 by volume) and 0.3 ml of 40 mM citric acid to stop the reaction. The mixture was vortexed and an organic solvent layer was evaporated to dryness under nitrogen gas. After 25 dissolving the dried organic layer in a fixed amount of the mixture of chloroform and methanol (2/1 by volume), it was spotted on a silica gel plate (Kiesel gel 60F254, E. Merck) and products were separated using a developer (the organic solvent layer of ethyl acetate/water/2,2,4-trimethylpentane/acetic acid = 11/10/5/2 by volume). After the radioactive position of the product was determined by means of a radioautography, an area equivalent to that of 5-hydroxyeicosatetraenoic acid (hereinafter referred to as "5-HETE") was scraped off, 30 and then its radioactivity was measured with a liquid scintillation counter. With regarding the amount of the generated 5-HETE as the 5-lipoxygenase inhibiting activity, the inhibition rate (%) in comparison with the

control group was calculated according to the following equation.

$$\text{Inhibition rate (\%)} = \frac{A - B}{A} \times 100$$

5

A: Value of radioactivity in the control group

B: Value of radioactivity in the test compound group

10

The 5-lipoxygenase inhibiting activity of the compounds of the present invention is shown in Table 6. The result shown in Table 6 proves that the compounds of the present invention sufficiently inhibits 5-lipoxygenase activity.

15

Table 6

20	Compound	Concentration*	Inhibition rate
	No.	(μM)	(%)
	2	10	78
	4	10	85
	7	1	88
25	8	1	61
	9	1	91
	10	1	23
	11	1	87
	12	1	84
30	13	1	86
	14	1	27
	16	10	28
	20	10	83
	22	10	63
35	23	10	85
	24	1	48

- continued -

	Compound No.	Concentration* (μ M)	Inhibition rate (%)
5	25	1	23
	26	1	84
	29	1	86
	30	1	87
10	31	1	49
	33	10	82
	35	10	89
	36	10	84
	37	10	89
	38	10	88
15	39	10	87
	40	10	87
	41	10	89
	42	10	88
	43	1	53
	45	1	36

(note) * Concentration of the test compound in the reaction mixture

25

The antibacterial activity against Gram-positive bacteria of the compound of the present invention was measured according to a standard method of Nippon Kagaku Ryoho Gakkai [Nippon Kagaku Ryoho Gakkaishi 30 (Journal of the Chemical therapy of Japan), 29, 76(1981)].

As for gram-positive bacteria, after cultivation in Mueller Hinton broth medium (made by Difco Co., Ltd.), there was prepared a bacterial suspension for 35 inoculation containing about 10^6 of the bacteria per 1 ml of the Mueller Hinton broth medium. On the other hand, the test compound was added to Mueller Hinton agar medium (made by Difco Co., Ltd.) so as to give agar plate medium

containing test samples which are twofold serial diluted. Then, the above-mentioned bacterial suspension for inoculation was streaked to each agar medium for about 2 cm with a looped nichrome wire (inner diameter: 5 about 1 mm).

After that the each agar plate medium was cultured at 37°C for 18 to 20 hours, the growth of the test bacteria was determined. The minimum concentration of the test compound, which completely inhibited the 10 growth of the test bacteria, was decided as a minimal inhibitory concentration (hereinafter referred to as "MIC").

As for acid-fast bacteria, after cultured in glycerol broth medium, there was prepared a bacterial 15 suspension for inoculation containing about 10^6 of the bacteria per 1 ml of the medium. On the other hand, there were prepared some glycerol Czapek agar plating media with adding the test compounds, and thereto the bacterial suspension for inoculation was streaked.

After the each agar plating medium, to which the acid-fast bacteria was streaked, was cultured at 37°C for 40 to 42 hours, MIC was determined as defined above.

As the result, each MIC of the compounds (1), 25 (2), (4), (11), (15), (16), (19) and (20) against Micrococcus luteus IFO 13867 was not more than 6 µg/ml, not more than 6 µg/ml, not more than 6 µg/ml, 12 µg/ml, 60 µg/ml, not more than 15 µg/ml, 50 µg/ml and not more than 50 µg/ml respectively; each MIC of the compounds 30 (1), (2), (11), (15), (16), (19), (20) and (41) against Bacillus subtilis IFO 3134 was not more than 6 µg/ml, not more than 6 µg/ml, not more than 6 µg/ml, 100 µg/ml, not more than 15 µg/ml, 100 µg/ml, 50 µg/ml and 25 µg/ml respectively; each MIC of the compounds (1), (2), 35 (11), (15), (16), (19), (20) and (41) against Staphylococcus aureus IFO 12732 was 12 µg/ml, 12 µg/ml, 25 µg/ml, 60 µg/ml, not more than 15 µg/ml, 100 µg/ml, 100 µg/ml and 50 µg/ml respectively; and each MIC of the

compounds (1), (15), (16), (19), (28), (30), (31), (32),
(33), (34), (35), (41), (42), (43), (44) and (45) against
Mycobacterium smegmatis ATCC 607 was 6 $\mu\text{g}/\text{ml}$, not more
than 15 $\mu\text{g}/\text{ml}$, not more than 15 $\mu\text{g}/\text{ml}$, not more than
5 6 $\mu\text{g}/\text{ml}$, not more than 15 $\mu\text{g}/\text{ml}$, not more than 6 $\mu\text{g}/\text{ml}$,
not more than 6 $\mu\text{g}/\text{ml}$, not more than 6 $\mu\text{g}/\text{ml}$, not more
than 15 $\mu\text{g}/\text{ml}$, not more than 6 $\mu\text{g}/\text{ml}$, 15 $\mu\text{g}/\text{ml}$, 25 $\mu\text{g}/\text{ml}$,
not more than 15 $\mu\text{g}/\text{ml}$, not more than 6 $\mu\text{g}/\text{ml}$, 2 $\mu\text{g}/\text{ml}$
and not more than 6 $\mu\text{g}/\text{ml}$ respectively.

10 Consequently, it was found that the compounds
of the present invention were effective on both gram-
positive and acid-fast bacteria.

15 Tyrosine kinase inhibiting activity of the
compound of the present invention was measured referring
to a method for measuring tyrosine kinase activity by G.
Carpenter or by S. Cohen et al. [J. Biol. Chem., 254,
4884(1979); J. Biol. Chem., 257, 1528(1982)].

20 Cell line A-431 derived from human carcinoma
(ATCC CRL1555) was cultured at 37°C under the condition
of 5 % CO_2 in Dulbecco's modified Eagle's medium (made by
NISSUI PHARMACEUTICAL CO., LTD.) containing 10 % by
volume fetal bovine serum, 50 $\mu\text{g}/\text{ml}$ of streptomycin, 50
IU/ml of penicillin G and 50 $\mu\text{g}/\text{ml}$ of kanamycin. The
obtained cells were treated according to the above-
25 mentioned method of Cohen or Carpenter et al. to give
membrane preparation containing epidermal growth factor
receptor-tyrosine kinase complex (hereinafter referred to
as "membrane preparation"). The membrane preparation was
employed in the following measurement without
30 solubilization.

A test compound dissolved in dimethylsulfoxide
(hereinafter referred to as "DMSO") was added to a
mixture of 20 mM of N-2-hydroxyethylpiperazine-N'-2-
ethanesulfonic acid buffer (pH 7.4), 1 mM of MnCl_2 , 7.5
35 μg of bovine serum albumin and the membrane preparation
(10 μg as protein). After incubation at 0°C for 5
minutes, 100 ng of epidermal growth factor (hereinafter
referred to as "EGF") was added thereto and the mixture

was further incubated at 0°C for 15 minutes. [γ -³²P]ATP (3000 Ci/mmol, 0.1 μ Ci) was added thereto to make final volume of 70 μ l. After incubation at 0°C for 15 minutes, 5 50 μ l of the reaction mixture was soaked into Whatman 3 MM filter paper (made by Whatman Ltd.) and immediately the reaction was stopped by an aqueous solution of 10 % by weight trichloroacetic acid containing 10 mM sodium pyrophosphate. The filter paper was sufficiently washed with the same solution and then washed with ethanol, and 10 dried. Radioactivity present in the filter paper was measured by liquid scintillation counter (A). Also, radioactivity was measured in case of the reaction without EGF (B), the reaction without the test compound (C), and the reaction without both EGF and the test 15 compound (D) as a control.

Tyrosine kinase inhibition rate (%) was calculated by the following equation.

$$20 \quad \text{Inhibition rate (\%)} = \frac{(C - D) - (A - B)}{C - D} \times 100$$

25 The result proves that the compounds of the present invention shows excellent tyrosine kinase inhibitory activity.

There is shown each tyrosine kinase inhibition rate of the compounds of the present invention in Table 7.

Table 7

Compound No.	Concentration* (μ M)	Inhibition rate (%)
1	1	23
2	1	20
3	1	45
4	1	74
5	1	42
7	10	59
8	10	69
9	10	50
10	1	40
11	10	52
12	10	30
14	1	43
15	1	100
16	1	100
17	1	25
18	1	87
19	1	74
20	1	46
21	1	98
22	1	84
23	10	60
24	1	37
25	10	72
26	10	62
27	1	58
28	1	66
29	1	63
30	1	70
31	10	41
32	1	74
33	10	69

- continued -

- continued -

	Compound No.	Concentration* (μM)	Inhibition rate (%)
5	34	1	63
	35	1	70
	36	10	59
	37	10	83
	38	10	85
10	39	10	43
	40	10	21
	41	10	70
	42	1	85
	43	10	95
15	44	1	80
	45	10	90

(note) * Concentration of the test compound in the reaction mixture

20

Additionally, the compounds of the present invention have UV absorbing activity and thus there are expected to use the compounds as the UV absorber in order to prevent a living body from erythema solare (generally called as sunburn), prevent organic high molecular materials (e.g. plastics, gum, paints and the like) from declining by UV-ray or prevent photographs and pictures from discoloring by UV-ray.

Each UV absorption spectrum of the compounds of the present invention was measured according to the conventional method, in which methanol was used as a solvent, and thereby molar extinction coefficient thereof was calculated. The results were shown in Table 8. It is found that, as shown in Table 8, the compounds of the present invention rather strongly absorb UV-ray.

Table 8

	Compound No.	λ max (nm)	molar extinction coefficient
5	4	257	1.87×10^4
		361	1.80×10^4
10	15	271	2.04×10^4
		348	2.11×10^4
15	16	249	1.51×10^4
		347	2.40×10^4
15	18	304	1.87×10^4

There was found the following point by using reverse transcriptase derived from Moloney-Murine

20 Leukemia Virus (hereinafter referred to as "M-MLV").

The compound of the present invention was dissolved in DMSO to give a 100 mM solution thereof. Then, the solution was diluted with distilled water containing DMSO to give a solution of the test compound 25 having a defined concentration. A mixed ratio of DMSO and distilled water was adjusted so that the concentration of DMSO at this time is 10 % by volume and a final concentration of DMSO at the beginning of a reaction is 1 % by volume.

30 The thus prepared solution of the test compound was mixed with a solution containing 50 mM of Tris-HCl buffer (pH 8.3), 8 mM of $MgCl_2$, 30 mM of NaCl, 50 mM of dithiothreitol (made by Wako Pure Chemical Industries Ltd.), 0.2 mM of thymidine-5'-triphosphate (made by Pharmacia K. K.) and 6 U/ml of reverse transcriptase derived from M-MLV (made by Pharmacia K. K.), and preincubated at 37°C for 30 minutes. After there was added thereto 10 μ g/ml of polyadenylic acid (made by PL

Biochemicals Co., Ltd.), 0.01 U/ml of oligodeoxy thymidylic acid (made by Pharmacia K. K.) and 10 μ Ci/ml of [methyl- 3 H] thymidine-5'-triphosphate (made by Amersham Japan Co., Ltd., 47 Ci/mmol) to give a reaction mixture, the mixture was further incubated at 37°C for 30 minutes, followed by cooling with ice to stop the reaction.

The radioactivity incorporated into deoxyribonucleic acids was measured according to the 10 method of Linteril et al (Science, 170, 447 to 449 (1967)). A defined volume of the reaction mixture was soaked into DE-81 filter paper (made by Whatman Ltd.), the filter paper was washed with 5 % by weight of Na_2HPO_4 solution for three times, and with distilled water and 15 ethanol successively, and then dried. Radioactivity contained in the filter paper was measured by liquid scintillation counter to give the each radioactivity of the test solution groups.

On the other hand, the same procedure as above 20 was carried out using DMSO-distilled water without the test compound instead of using the test solution, to give the value of radioactivity of a control group.

Reverse transcriptase derived from M-MLV inhibition rate (%) was calculated by the following 25 equation.

$$\text{Inhibition rate (\%)} = \frac{A - B}{A} \times 100$$

30 A: radioactivity of the control group
B: radioactivity of the test solution group

The typical examples of reverse transcriptase 35 derived from M-MLV inhibiting activity of the compounds of the present invention are shown in Table 9.

The results proves that the compounds shown in Table 1 have strong inhibiting activity against reverse

transcriptase derived from M-MLV and thus it can be expected that the compounds show sufficient growth inhibiting effect on retrovirus having reverse transcriptase.

5

Table 9

	Compound No.	Concentration* (μ M)	Inhibition rate (%)
10	1	1	96
	2	1	95
	5	10	87
	6	10	98
	7	1	98
	8	1	98
	9	1	73
	10	10	61
	11	1	94
	15	10	59
15	19	1	75
	20	10	97
	24	1	91
	26	10	76
	27	1	73
	31	10	61
20	42	10	50

(Note) * Concentration of the test compound in the reaction mixture

(Acute toxicity test)

In each group, 6 female ICR mice weighing 23 to 26 g were employed. The compounds (1) to (45) suspended in an aqueous solution of 2.5 % gum arabic containing 0.2 % Tween 80 were administered orally to each mouse in a volume of 0.1 ml/10 g body weight. The general symptoms of the mice were observed for two weeks after the

administration. The LD₅₀ (mg/kg) values were estimated from the ratio of the number of dead mice to the number of mice used. As a result, there were observed no dead mice at a dose of 500 mg/kg. The LD₅₀ of the compounds 5 (1) to (45) of the present invention was estimated to be not less than 500 mg/kg, which proved a low toxicity of the compounds of the present invention.

(Preparations and Dosage)

The antiallergic agents, 5-lipoxygenase 10 inhibiting agents, antibacterial agents, tyrosine kinase inhibiting agents, UV absorber or reverse transcriptase inhibiting agents of the present invention can be administered orally, rectally, or parenterally in pharmaceutical dosage form, for example, tablets, 15 capsules, fine subtilaes, syrups, suppositories, ointments, injections, and the like.

As for excipients in the formulations of the antiallergic agents, 5-lipoxygenase inhibiting agents, antibacterial agents, tyrosine kinase inhibiting agents, 20 UV absorber or reverse transcriptase inhibiting agents of the present invention, organic or inorganic pharmaceutically acceptable excipient material is employed in a solid or liquid state, which is usually inactive and suited for oral, rectal or parenteral 25 administration. Examples of such excipient are, for instance, crystalline cellulose, gelatin, lactose, starch, magnesium stearate, talc, vegetable or animal fat and oil, gum, polyalkyleneglycol, and the like. The ratio of the compound of the present invention having the 30 formula (I), contained in the antiallergic agents, 5-lipoxygenase inhibiting agents, antibacterial agents, tyrosine kinase inhibiting agents, UV absorber or reverse transcriptase inhibiting agents as an active ingredient in the formulation any vary in the range from 0.2 to 100 35 %.

The antiallergic agents, 5-lipoxygenase inhibiting agents, antibacterial agents, the tyrosine kinase inhibiting agents, UV absorber or reverse

transcriptase inhibiting agents of the present invention may contain other antiallergic agents, 5-lipoxygenase inhibiting agents, antibacterial agents, tyrosine kinase inhibiting agents, UV absorber, reverse transcriptase 5 inhibiting agents or any other drugs, which are compatible with the agents of the present invention. In this case, it is needless to say that the antiallergic agents, 5-lipoxygenase inhibiting agents, antibacterial agents, tyrosine kinase inhibiting agents, UV absorber or 10 reverse transcriptase inhibiting agents of the present invention may not be the principal ingredients in the formulation.

The antiallergic agents, 5-lipoxygenase inhibiting agents, antibacterial agent, the tyrosine 15 kinase inhibiting agents, UV absorber or reverse transcriptase inhibiting agents of the present invention are administered at a dose where the desired activity is generally achieved without any side effects.

Though a practical dose should be determined by 20 a physician, the compound of the present invention having the formula (I), which is an active ingredient of the agents of the present invention, is generally administered at a dose from 10 mg to 10 g, preferably from about 20 mg to 5 g, for an adult a day. The 25 antiallergic agents, 5-lipoxygenase inhibiting agents, antibacterial agents, tyrosine kinase inhibiting agents, UV absorber or reverse transcriptase inhibiting agents of the present invention can be administered as a pharmaceutical formulation which contains 1 mg to 5 g, 30 preferably 3 mg to 1 g of the compound having the formula (I) as an active ingredient.

The present invention is more specifically described and explained by means of the following Examples. It is to be understood that the present 35 invention is not limited to Examples.

Example 1

[Preparation of the compound (1)]

In 100 ml of benzene were dissolved 1.37 g of 3,5-diphenyl-4-hydroxybenzaldehyde and 0.82 g of rhodanine, and thereto 0.1 ml of piperidine and 0.5 ml of acetic acid were added. The mixture was heated under reflux for 5 hours in Dean-Stark apparatus while removing water produced. After cooling, the deposited crystals were filtered and subjected to crystallization from a mixed solvent of benzene and acetone to give 1.2 g (yield: 62 %) of the compound (1).

The melting point and data of elementary analysis of the obtained compound (1) are shown in Table 1. And results of $^1\text{H-NMR}$ and IR of the obtained compound (1) are shown in Table 2.

15

Example 2

[Preparation of the compound (4)]

In 70 ml of benzene were dissolved 1.51 g of 3,5-dibenzyl-4-hydroxybenzaldehyde and 0.67 g of oxyindol, and thereto 0.1 ml of piperidine and 0.5 ml of acetic acid were added. The mixture was heated under reflux for 5 hours in Dean-Stark apparatus while removing water produced. After cooling, the solvent was distilled away under reduced pressure. The obtained residue was dissolved in 200 ml of chloroform, washed with water and dried with sodium sulfate. Chloroform was distilled away under reduced pressure, the residue was subjected to crystallization from ethanol to give 600 mg (yield: 29 %) of the compound (4).

The melting point and data of elementary analysis of the obtained compound (4) are shown in Table 1. And results of $^1\text{H-NMR}$ and IR of the obtained compound (4) are shown in Table 2.

35

Example 3

[Preparation of the compound (5)]

In 70 ml of benzene were dissolved 0.61 g of 3,5-dibenzyl-4-hydroxybenzaldehyde and 0.39 g of 2H-1,4-benzothiazine-3(4H)-one-1,1-dioxide, and thereto 0.1 ml

of piperidine and 0.5 ml of acetic acid were added. The mixture was heated under reflux for 5 hours in Dean-Stark apparatus while removing water produced. After cooling, the solvent was distilled away under reduced pressure.

- 5 The obtained residue was subjected to a column-chromatography (carrier: silica-gel) and eluted with mixed solvent of chloroform/methanol (98/2: v/v). A fraction containing the desired compound was concentrated and the obtained residue was subjected to crystallization
10 from benzene to give 180 mg (yield: 19 %) of the compound (5).

The melting point and data of elementary analysis of the obtained compound (5) are shown in Table 1. And results of $^1\text{H-NMR}$ and IR of the obtained compound
15 (5) are shown in Table 2.

Example 4

[Preparation of the compound (7)]

- To 100 ml of benzene were added 2.6 g of 5-phenylthiomethylprotocatechuic aldehyde, 1.33 g of rhodanine, 0.1 ml of piperidine and 0.5 ml of acetic acid. The mixture was heated under reflux for 5 hours in Dean-Stark apparatus while removing water produced.
20 After cooling, the deposited crystals were filtered off from the reaction mixture and the obtained crystals were recrystallized from ethanol to give 2.78 g (yield: 74 %) of the compound (7).

The melting point and data of elementary analysis of the obtained compound (7) are shown in Table 1. And results of $^1\text{H-NMR}$ and IR of the obtained compound
30 (7) are shown in Table 2.

Example 5

[Preparation of the compound (11)]

- In 70 ml of benzene were dissolved 0.78 g of 5-phenylthiomethylprotocatechuic aldehyde and 0.4 g of oxyindol, and thereto 0.1 ml of piperidine and 0.5 ml of acetic acid were added. The mixture was heated under

reflux for 5 hours in Dean-Stark apparatus while removing water produced. After cooling, the deposited crystals were filtered off from the reaction mixture and washed with benzene. And the obtained crystals were recrystallized from a mixed solvent of benzene and acetone to give 1.0 g (yield: 90 %) of the compound (11).

The melting point and data of elementary analysis of the obtained compound (11) are shown in Table 1. And results of $^1\text{H-NMR}$ and IR of the obtained compound (11) are shown in Table 2.

Example 6

[Preparation of the compound (12)]

A condensation of 0.7 g of 3-benzyloxy-4-hydroxy-5-phenylthiomethylbenzaldehyde and 0.27 g of oxyindol was carried out in the same manner as in the above Example 1. And the obtained residue was subjected to a column-chromatography (carrier: silica-gel) and eluted with mixed solvent of chloroform/methanol (98/2: v/v). After a fraction containing the desired compound was concentrated under reduced pressure, the fraction was subjected to crystallization from ethanol to give 0.62 g (yield: 66 %) of the compound (12).

The melting point and data of elementary analysis of the obtained compound (12) are shown in Table 1. And results of $^1\text{H-NMR}$ and IR of the obtained compound (12) are shown in Table 2.

Example 7

[Preparation of the compound (15)]

In 200 ml of benzene were dissolved 2.90 g of 3,5-diphenyl-4-hydroxybenzaldehyde and 840 mg of α -cyanoacetamide, and thereto 0.1 ml of piperidine and 0.5 ml of acetic acid were added. The mixture was heated under reflux for 5 hours in Dean-Stark apparatus while removing water produced. After the solvent was distilled away under reduced pressure, the obtained residue was subjected to a column-chromatography (carrier: silica-

gel) and eluted with a mixed solvent of chloroform/methanol (98/2: v/v). A fraction containing the desired compound was concentrated and the obtained residue was subjected to crystallization from a mixed solvent of benzene and acetone to give 11.15 g (yield: 32 %) of the compound (15).

The melting point and data of elementary analysis of the obtained compound (15) are shown in Table 1. And results of $^1\text{H-NMR}$ and IR of the obtained compound (15) are shown in Table 2.

Example 8

[Preparation of the compound (17)]

To 50 ml of acetonitrile were added 760 mg of 3,5-dibenzyl-4-hydroxybenzaldehyde and 1.04 g of α -triphenylphosphoranylidene- γ -butyrolactone. The mixture was heated and stirred overnight at 80°C. After cooling, the deposited crystals were filtered and subjected to crystallization from ethanol to give 450 mg (yield: 48 %) of the compound (17).

25

Example 9

[Preparation of the compound (18)]

In 50 ml of dried benzene was suspended 0.6 g of sodium hydride under nitrogen atmosphere, to which a solution of 1.73 g of 3,5-dibenzyl-4-methoxymethoxybenzaldehyde and 1.27 g of N-acetylpyrrolidone dissolved in 20 ml of benzene was added dropwise, subsequently heated and stirred overnight at 50°C. After cooling, the reaction solution was added to an ice water and extracted with chloroform. The solvent was distilled away from the obtained extract under reduced pressure. The obtained residue was dissolved in 50 ml of dried methylene chloride, which was added with 4 ml of trifluoroacetic

acid and stirred for 3 hours at room temperature. The solvent was distilled away from the solution under reduced pressure, the obtained residue was subjected to a column-chromatography (carrier: silica-gel) and eluted with mixed solvent of chloroform/methanol (98/2: v/v). A fraction containing the desired compound was concentrated and the obtained residue was subjected to crystallization from ethanol to give 450 mg (yield: 21 %) of the compound (18).

10 The melting point and date of elementary analysis of the obtained compound (18) are shown in Table 1. And results of $^1\text{H-NMR}$ and IR of the obtained compound (18) are shown in Table 2.

15 Example 10

[Preparation of the compound (19)]

20 In 100 ml of benzene were dissolved 1.37 g of 3,5-diphenyl-4-hydroxybenzaldehyde and 0.88 g of 1-phenyl-3,5-pyrazolidinedion, and thereto 0.1 ml of piperidine and 0.5 ml of acetic acid were added. The mixture was heated under reflux for 5 hours in Dean-Stark apparatus while removing water produced. After cooling, the deposited crystals were filtered and subjected to crystallization from ethanol to give 600 mg (yield: 28 %) of the compound (19).

25 The melting point and data of elementary analysis of the obtained compound (19) are shown in Table 1. And results of $^1\text{H-NMR}$ and IR of the obtained compound (19) are shown in Table 2.

30

Example 11

[Preparation of the compound (25)]

35 To 100 ml of benzene were added 1.37 g of 3,5-diphenyl-4-hydroxybenzaldehyde, 0.82 g of rhodanine, 0.1 ml of piperidine and 0.5 ml of acetic acid. The mixture was heated under reflux for 5 hours in Dean-Stark apparatus while removing water produced. The deposited crystals was filtered off from the reaction mixture.

After drying, the deposited crystals were heated under reflux for 5 hours with 1.1 ml of benzylamine in 50 ml of ethanol. After cooling, the solvent was distilled away under reduced pressure. The residue was subjected to a column-chromatography (carrier: silica-gel) and eluted with mixed solvent of chloroform/methanol (100/2: v/v).
5 After a fraction containing the desired compound was concentrated under reduced pressure, the fraction was subjected to crystallization from ethanol to give 0.60 g
10 (yield: 26 %) of the compound (25).

The melting point and data of elementary analysis of the obtained compound (25) are shown in Table 1. And results of $^1\text{H-NMR}$ and IR of the obtained compound (25) are shown in Table 2.
15

Example 12

[Preparation of the compound (26)]

To 100 ml of benzene were added 3.02 g of 3,5-dibenzyl-4-hydroxybenzaldehyde, 1.33 g of rhodanine, 0.1 ml of piperidine and 0.5 ml of acetic acid. The mixture was heated under reflux for 5 hours in Dean-Stark apparatus while removing water produced. The deposited crystals were filtered off from the reaction mixture. After drying, the deposited crystals were heated under reflux for 5 hours with 2.2 ml of benzylamine in 100 ml of ethanol. After cooling, the solvent was distilled away under reduced pressure. The obtained residue was subjected to a column-chromatography (carrier: silica-gel) and eluted with mixed solvent of chloroform/methanol (100/2: v/v). After a fraction containing the desired compound was concentrated under reduced pressure, the fraction was subjected to crystallization from ethanol to give 2.0 g (yield: 41 %) of the compound (26).
20
25
30

The melting point and data of elementary analysis of the obtained compound (26) are shown in Table 1. And results of $^1\text{H-NMR}$ and IR of the obtained compound (26) are shown in Table 2.
35

Example 13

[Preparation of the compound (28)]

To 100 ml of ethanol were added 4.04 g of 5-(3-ethoxy-4-hydroxy-5-phenylthiomethylbenzylidene)-rhodanine obtained by the condensation reaction of 5-phenylthiomethylvanillin and rhodanine in the same manner as above and 2.2 ml of benzylamine. The mixture was heated under reflux for 5 hours. After cooling, the solvent was distilled away under reduced pressure. The obtained residue was subjected to a column-chromatography (carrier: silica-gel) and eluted with chloroform. After a fraction containing the desired compound was concentrated under reduced pressure, the fraction was subjected to crystallization from ethanol to give 1.96 g (yield: 38 %) of the compound (28).

20

Example 14

[Preparation of the compound (30)]

To 50 ml of ethanol were added 0.80 g of 5-(3-n-butyloxy-4-hydroxy-5-benzylbenzylidene)-rhodanine obtained by the condensation reaction of 3-n-butyloxy-4-hydroxy-5-benzylbenzaldehyde and rhodanine in the same manner as above and 0.44 ml of benzylamine. The mixture was heated under reflux for 5 hours. After cooling, the solvent was distilled away under reduced pressure. The obtained residue was subjected to a column-chromatography (carrier: silica-gel) and eluted with a mixed solvent of chloroform/methanol (10/1: v/v). After a fraction containing the desired compound was concentrated under reduced pressure, the fraction was subjected to crystallization from ethanol to give 0.72 g (yield: 76 %) of the compound (30).

The melting point and data of elementary analysis of the obtained compound (30) are shown in Table

1. And results of $^1\text{H-NMR}$ and IR of the obtained compound (30) are shown in Table 2.

Example 15

5 [Preparation of the compound (33)]

In 30 ml of ethanol was dissolved 966 mg of 5-(3,5-diisopropyl-4-hydroxybenzylidene)-rhodanine, and thereto 624 mg of benzylamine was added. The mixture was heated under reflux for 5 hours. Ethanol was distilled away under reduced pressure, and the obtained residue was dissolved in chloroform. After washing with water, the solution was concentrated to dryness. The obtained concentrate was subjected to a column-chromatography (carrier: silica-gel) and eluted with chloroform. A fraction containing the desired compound was collected, concentrated and dried to give 660 mg (yield: 56 %) of the compound (33).

The melting point and data of elementary analysis of the obtained compound (33) are shown in Table 1. And results of $^1\text{H-NMR}$ and IR of the obtained compound (33) are shown in Table 2.

Example 16

[Preparation of the compound (34)]

25 In 30 ml of ethanol was dissolved 966 mg of 5-(3,5-diisopropyl-4-hydroxybenzylidene)-rhodanine, and thereto 726 mg of phenethylamine was added. The mixture was heated under reflux for 12 hours. Ethanol was distilled away under reduced pressure, and the obtained residue was dissolved in chloroform. After washing with water, the solution was subjected to a column-chromatography (carrier: silica-gel) and eluted with chloroform. A fraction containing the desired compound was collected, concentrated, dried and subjected to crystallization to give 600 mg (yield: 68 %) of the compound (34).

The melting point and data of elementary analysis of the obtained compound (34) are shown in Table

1. And results of $^1\text{H-NMR}$ and IR of the obtained compound (34) are shown in Table 2.

Example 17

5 [Preparation of the compound (35)]

In 30 ml of ethanol was dissolved 966 mg of 5-(3,5-diisopropyl-4-hydroxybenzylidene)-rhodanine, and thereto 773 mg of p-fluorobenzylamine. The mixture was heated under reflux for 7 hours. Ethanol was distilled away under reduced pressure, and the obtained residue was dissolved in chloroform. After washing with water, the solution was subjected to a column-chromatography (carrier: silica-gel) and eluted with chloroform. A fraction containing the desired compound was collected, concentrated and dried to give 660 mg (yield: 52 %) of the compound (35).

The melting point and data of elementary analysis of the obtained compound (35) are shown in Table 1. And results of $^1\text{H-NMR}$ and IR of the obtained compound (35) are shown in Table 2.

Example 18

[Preparation of the compound (39)]

In 30 ml of ethanol was dissolved 966 mg of 5-(3,5-diisopropyl-4-hydroxybenzylidene)-rhodanine, and thereto 726 mg of p-methylbenzylamine was added. The mixture was heated under reflux for 12 hours. Ethanol was distilled away under reduced pressure, and the obtained residue was dissolved in chloroform. After washing with water, the solution was subjected to a column-chromatography (carrier: silica-gel) and eluted with chloroform. A fraction containing the desired compound was collected, concentrated, dried and subjected to crystallization to give 900 mg (yield: 30 %) of the compound (39).

The melting point and data of elementary analysis of the obtained compound (39) are shown in Table 1. And results of $^1\text{H-NMR}$ and IR of the obtained compound

(39) are shown in Table 2.

Example 19

[Preparation of the compound (41)]

5 In 30 ml of ethanol was dissolved 966 mg of 5-(3,5-diisopropyl-4-hydroxybenzylidene)-rhodanine, and thereto 681 mg of p-aminosulfonylbenzylamine hydrochloride and 606 mg of triethylamine. The mixture was heated under reflux for 6 hours. Ethanol was
10 distilled away under reduced pressure, and the obtained residue was dissolved in chloroform. After washing with water, the solution was subjected to a column-chromatography (carrier: silica-gel) and eluted with a mixed solvent of chloroform/ethanol (9/1: v/v). A
15 fraction containing the desired compound was collected, concentrated and dried to give 400 mg (yield: 27 %) of the compound (41).

The melting point and data of elementary analysis of the obtained compound (41) are shown in Table
20 1. And results of $^1\text{H-NMR}$ and IR of the obtained compound (41) are shown in Table 2.

Example 20

[Preparation of the compound (42)]

25 In 30 ml of ethanol was dissolved 1.61 g of 5-(3,5-diisopropyl-4-hydroxybenzylidene)-rhodanine, and thereto 1.30 g of p-aminobenzylamine was added. The mixture was heated under reflux for 5 hours. Ethanol was distilled away under reduced pressure, and the obtained residue was subjected to a crystallization from chloroform to give 570 mg (yield: 56 %) of the compound (42).

The melting point and data of elementary analysis of the obtained compound (42) are shown in Table
35 1. And results of $^1\text{H-NMR}$ and IR of the obtained compound (42) are shown in Table 2.

Example 21

[Preparation of the compound (44)]

In 30 ml of ethanol was dissolved 966 mg of 5-(3,5-diisopropyl-4-hydroxybenzylidene)-rhodanine, and thereto 707 mg of 2-aminomethylthiophene was added. The 5 mixture was heated under reflux for 3 hours. Ethanol was distilled away under reduced pressure, and the obtained residue was dissolved in chloroform. After washing with water, the solution was subjected to a column-chromatography (carrier: silica-gel) and eluted with chloroform. A fraction containing the desired compound 10 was collected, concentrated and dried to give 300 mg (yield: 24 %) of the compound (44).

The melting point and data of elementary analysis of the obtained compound (44) are shown in Table 15 1. And results of $^1\text{H-NMR}$ and IR of the obtained compound (44) are shown in Table 2.

Example 22


[Preparation of the compound (45)]

In 30 ml of ethanol was dissolved 966 mg of 5-(3,5-diisopropyl-4-hydroxybenzylidene)-rhodanine, and thereto 648 mg of 2-aminomethylpyridine was added. The 20 mixture was heated under reflux for 4 hours. Ethanol was distilled away under reduced pressure, and the obtained residue was dissolved in chloroform. After washing with water, the solution was subjected to a column-chromatography (carrier: silica-gel) and eluted with a 25 mixed solvent of chloroform/ethanol (20/1: v/v). A fraction containing the desired compound was collected, concentrated and dried to give 200 mg (yield: 17 %) of the compound (45).

The melting point and data of elementary analysis of the obtained compound (45) are shown in Table 1. And results of $^1\text{H-NMR}$ and IR of the obtained compound 35 (45) are shown in Table 2.

CLAIMS

1 1. A hydroxystyrene derivative represented by
 2 the formula (I):



4 wherein when R¹ and R² are the same or different and each
 5 is phenyl group, benzyl group or phenethyl group, or R¹
 6 is a group having the formula: R⁵O- in which R⁵ is
 7 hydrogen atom, an alkyl group having 1 to 5 carbon atoms
 8 or benzyl group and R² is benzyl group or a group having
 9 the formula: PhSCH₂, R³ and R⁴ are taken together to
 10 represent a group having the formula: -CONH-CS-S-, a

11 group having the formula: -CONH-

12 formula: -CONH-

SO₂ or a group having the formula:

13 -CO-N=C-S- in which R⁶ is a group having the
 $\begin{array}{c} \text{NH}(\text{CH}_2)^{\text{n}^1}\text{R}^6 \end{array}$

14 formula:
 $(\text{X}^1)^{\text{m}^1}$ [in which X¹ is hydrogen atom, a
 15 halogen atom, methyl group, ethyl group, an alkoxy group
 16 having the formula: R⁷O- (in which R⁷ is methyl or ethyl
 17 group), nitro group, aminosulfonyl group or amino group,
 18 and m¹ is 1 or 2], pyridyl group, furyl group or thienyl
 19 group, and n¹ is 0 or an integer of 1 to 3;
 20 when R¹ and R² are the same or different and each is
 21 phenyl group, benzyl group or phenethyl group, or R¹ is a
 22 group having the formula: R⁵O- in which R⁵ is as defined
 23 above, and R² is benzyl group, R³ is cyano group and R⁴
 24 is carbamoyl group, or R³ and R⁴ are taken together to
 25 represent a group having the formula: -CO-Y-CH₂CH₂- in
 26 which Y is oxygen atom or -NH-, or a group having the

27 formula: $-\text{CO}-\underset{\text{Ph}}{\text{N}}-\text{NH}-\text{CO}-$; and

28 when R^1 and R^2 are the same or different and each is an
29 alkyl group having 1 to 3 carbon atoms, R^3 and R^4 are
30 taken together to represent a group having the formula:
31 $-\text{CO}-\underset{\text{NH}(\text{CH}_2)^{n^1}\text{R}^6}{\text{N}}=\text{C}-\text{S}-$ in which n^1 and R^6 are as defined above,
32 or a salt thereof.

1 2. The hydroxystyrene derivative of Claim 1,
2 wherein R^1 and R^2 are the same or different and each is
3 phenyl group, benzyl group or phenethyl group, or R^1 is a
4 group having the formula: $\text{R}^5\text{O}-$ in which R^5 is as defined
5 above, and R^2 is benzyl group or group: PhSCH_2 , and R^3
6 and R^4 are taken together to represent a group having the
7 formula: $-\text{CONH}-\text{CS}-\text{S}-$, a group having the formula:

8 $-\text{CONH}$  , a group having the formula:

9 $-\text{CONH}$  SO_2- or a group having the formula:

10 $-\text{CO}-\underset{\text{NH}(\text{CH}_2)^{n^1}\text{R}^6}{\text{N}}=\text{C}-\text{S}-$ in which n^1 and R^6 are as defined
above, or a salt thereof.

1 3. The hydroxystyrene derivative of Claim 1,
2 wherein R^1 and R^2 are the same or different and each is
3 phenyl group, benzyl group or phenethyl group, or R^1 is a
4 group having the formula: $\text{R}^5\text{O}-$ in which R^5 is as defined
5 above, and R^2 is benzyl group, and R^3 is cyano group and
6 R^4 is carbamoyl group, or R^3 and R^4 are taken together to
7 represent a group having the formula: $-\text{CO}-\text{Y}-\text{CH}_2\text{CH}_2-$ in
8 which Y is as defined above, or a group having the
9 formula: $-\text{CO}-\underset{\text{Ph}}{\text{N}}-\text{NH}-\text{CO}-$, or a salt thereof.

1 4. The hydroxystyrene derivative of Claim 1,
2 wherein R^1 and R^2 are the same or different and each is
3 an alkyl group having 1 to 3 carbon atoms, and R^3 and R^4

4 are taken together to represent a group having the
5 formula:

6 -CO-N=C-S- in which n^1 and R^6 are as defined
7 $\text{NH(CH}_2\text{)}^{n^1}\text{R}^6$
above, or a salt thereof.

1 5. An antiallergic agent containing the
2 hydroxystyrene derivative of Claim 1 or a
3 pharmaceutically acceptable salt thereof as an active
4 ingredient.

1 6. A 5-lipoxygenase inhibiting agent containing
2 the hydroxystyrene derivative of Claim 1 or a
3 pharmaceutically acceptable salt thereof as an active
4 ingredient.

1 7. An antibacterial agent containing the
2 hydroxystyrene derivative of Claim 1 or a
3 pharmaceutically acceptable salt thereof as an active
4 ingredient.

1 8. A tyrosine kinase inhibiting agent
2 containing the hydroxystyrene derivative of Claim 1 or a
3 pharmaceutically acceptable salt thereof as an active
4 ingredient.

1 9. An ultraviolet absorber containing the
2 hydroxystyrene derivative of Claim 1 or a
3 pharmaceutically acceptable salt thereof as an active
4 ingredient.

1 10. A reverse transcriptase inhibiting agent
2 containing the hydroxystyrene derivative of Claim 1 or a
3 pharmaceutically acceptable salt thereof as an active
4 ingredient.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/JP88/00254

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶

According to International Patent Classification (IPC) or to both National Classification and IPC Int.C1⁴
 C07C121/75, 120/00, C07D207/38, 231/36, 277/36, 307/32,
 A61K7/42, 31/275, 31/34, 31/425, C09K3/00, C12N9/99

II. FIELDS SEARCHED

Minimum Documentation Searched ⁷

Classification System	Classification Symbols
IPC	C07C121/75, 120/00, C07D207/38, 231/36, 277/36, 307/32, A61K7/42, 31/275, 31/34, 31/425, C09K3/00, C12N9/99
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸	

III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹

Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
P	JP, A, 62-111962 (Kanegafuchi Chemical Industry Co., Ltd.) 22 May 1987 (22. 05. 87) & EP, A, 211363	1-10
Y	JP, A, 62-39523 (Kanegafuchi Chemical Industry Co., Ltd.) 20 February 1987 (20. 02. 87) (Family: none)	1-8, 10
Y	JP, A, 62-39522 (Kanegafuchi Chemical Industry Co., Ltd.) 20 February 1987 (20. 02. 87) (Family: none)	1-8, 10
Y	JP, A, 58-79920 (Kanegafuchi Chemical Industry Co., Ltd.) 13 May 1983 (13. 05. 83) (Family: none)	1-4
Y	JP, A, 49-103929 (Sumitomo Chemical Co., Ltd.)	1-4, 9

¹⁰ Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

June 1, 1988 (01. 06. 88)

Date of Mailing of this International Search Report

June 13, 1988 (13. 06. 88)

International Searching Authority

Japanese Patent Office

Signature of Authorized Officer

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

	2 October 1974 (02. 10. 74) & NL, A, 7401297 & DE, A, 2402197 & FR, A, 2216336 & US, A, 3912519 & GB, A, 1437551 & DE, A, 2402197 & CA, A, 1014464 & NL, A, 156744	
A	JP, A, 60-237033 (Imperial Chemical Industries P.L.C.) 25 November 1985 (25. 11. 85) & EP, A, 154528 & NO, A, 8500887 & AU, A, 8539446 & DK, A, 8501048 & FI, A, 8500888 & ZA, A, 8501268 & PT, A, 80075 & HU, A, T38087 & ES, A, 8701139 & ES, A, 8706596	1-8, 10

v. OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE¹⁰

This International search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. Claim numbers.....because they relate to subject matter¹² not required to be searched by this Authority, namely:

2. Claim numbers.....because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out¹³, specifically:

vi. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING¹¹

This International Searching Authority found multiple inventions in this international application as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- The additional search fees were accompanied by applicant's protest.
- No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

A	JP, A, 60-215636 (Rhône-Poulenc Santé) 29 October 1985 (29. 10. 85) & FR, A, 2561641 & EP, A, 161132 & US, A, 4594460 & CA, A, 1217779 & EP, A, 161132 & DE, A, 3560180	1-4
---	---	-----

V. OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE¹⁰

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. Claim numbers., because they relate to subject matter¹² not required to be searched by this Authority, namely:

2. Claim numbers., because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out¹³, specifically:

VI. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING¹¹

This International Searching Authority found multiple inventions in this international application as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- The additional search fees were accompanied by applicant's protest.
- No protest accompanied the payment of additional search fees.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.